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ABSTRACT 
The prevalence of human cytomegalovirus (HCMV) ranges from 40% to 100% worldwide. A 
primary HCMV infection results in a lifelong latent or persistent infection. In healthy people, 
HCMV infection is often asymptomatic, but in immunosuppressed individuals it can cause life-
threatening disease, and HCMV congenital infection may result in fetal malformation. 
Increasing evidence implies that HCMV infection is associated with different malignancies. 
Several studies have suggested different mechanisms by which HCMV can modulate the 
tumour and the tumour environment, which could be of relevance in tumour development and 
progression. However, the role of HCMV in cancer has remained highly controversial. The 
studies in this thesis investigated the possible role of HCMV in cancer, with a special focus on 
HCMV encoded-miRNAs. HCMV encodes at least 26 miRNAs, and are expressed during the 
lytic as well as latent phase of infection. Viral miRNAs are identified to target both host and 
viral mRNA transcripts and thereby regulate protein expression. They modulate various 
biological functions of the host cell and the virus life cycle by mediating latency, viral 
replication, cell cycle control, vesicle trafficking, virus assembly and immune evasion 
strategies. 
 
In study I (Manuscript), we discovered a novel genetic variant of HCMV lacking intron 2 of 
the major immediate early (MIE) gene in 48% tumour samples obtained from breast, colon, 
neuroblastoma, medulloblastoma and glioblastoma patients. In contrast, this variant was less 
frequently detected in healthy donors, and in patients with HCMV viremia or myocardial 
infarction. We found, three clinical isolate that contained both the wild type HCMV and the 
variant HCMV strains; the variant was successfully plaque purified from endothelial cells 
(HUVEC). Electron microscopy analysis found dense body like particles but no HCMV 
particles in variant positive HUVEC cells. The variant expressed cytoplasmic IE proteins, 
which were of multiple sizes. Our results demonstrate a high prevalence of a novel genetic 
variant of HCMV in cancer patients, which may represent a new virus strain with potential 
oncogenic properties that warrants further investigation. 
 
In study II (Published in PlosONE 2014), the HCMV microRNA miR-UL112-3p suggested 
to mediate the latency and immune evasion strategies, also highly expressed in hypertension 
patients and associated with increased risk of hypertension. In our study, we detected miR-
UL112-3p in plasma/serum of 52% (14/27) of Diabetic Mellitus, 25% (5/20) of Glioblastoma 
patients, in 5% (1/20) of Rheumatoid Arthritis patients and in 10% (2/20) of Healthy Controls. 
Anti-HCMV IgG was detected in 85%, 65%, 75% of patients and 70% of healthy controls, 
respectively. Anti-HCMV IgM was found only in one Glioblastoma patient of the 87 examined 
patients and controls. We didn’t found significant association between serology and miR-
Ul112-3p. 
In study III (Accepted for publication), HCMV infected cells produce mature virions and 
defective particles called dense bodies (DBs). In this study, we purified these particles, and 
found that virions and DBs incorporate viral as well as host encoded RNAs and miRNAs within 
the particles. Furthermore, we demonstrated that the particle associated miRNAs can be 
delivered to host cells, are biologically functional, which may affect cellular processes. 
 
In study IV (Published in PLOS One 2013), we found that HCMV proteins IE and LA were 
abundantly expressed in all breast cancer tissue specimens examined (n=73) and 94% of their 
paired sentinel lymph node specimens (n=32/34) with metastases. Moreover, we also found 
HCMV IE and LA proteins in 60% (20/35) sentinel lymph node specimens without metastases. 
HCMV infections were mostly confined to the neoplastic cells, while some inflammatory cells 
were also HCMV positive in 79% of lymph nodes with metastases and 60% in metastatic free 
lymph nodes. We didn’t had enough sample to perform survival analysis, as only six patients 
died of breast cancer in this cohort. These six patients had high grade HCMV infection. High 
grade HCMV IE staining are more prevalent, due to the less patients in each group no further 
statistical correlation analyses with clinical prognostic factors (ER-α, PR and Elston grade) are 
reported. We conclude that, higher prevalence of HCMV proteins found in lymph nodes with 
metastasis than lymph nodes with metastasis, and bigger cohort is required to perform the 
correlation analysis. 
Another project by Dr. Afsar Rahbar in our lab, using more number of patients found the high 
expression of HCMV IE proteins in breast cancer tumours tissues inversely correlation with 
ER, PR and HER2 levels (manuscript in revision).  
In study V (Manuscript) we further studied this phenomenon in vitro; HCMV infection 
resulted in significant downregulation of mRNA and protein levels of ER-α, PR and Her-2 in 
breast cancer cell lines. This effect was dependent on viral gene expression. We found potential 
viral miRNAs which can targets of ER-α (miR-UL22A-3p, miRUL36-3p and miR-US25-2-
3p) and PR (miR-UL22A-3p). Overexpression of each viral miRNAs in a breast cancer cell 
line resulted in downregulation of mRNA and protein levels of ER-α and PR. Thus, HCMV 
may promote the establishment of triple negative breast cancer, through viral miRNA induced 
downregulation of ER-α, PR (and Her-2 by a yet unidentified mechanism). Antiviral therapy 
could hence be a potential alternative treatment strategy for selected breast cancer patients. 
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1 HUMAN CYTOMEGALOVIRUS (HCMV) 
 
1.1 The discovery of HCMV 
The first observation of what is believed to be cytomegalovirus (CMV) was made by a German 
pathologist, Ribbert, in the year of 1881. He described stillborn babies who had died of what 
he thought was syphilis like symptoms. He found cells of kidney enlarged in all these babies. 
However, he was unable to explain the cause of this condition. In the year 1904, Jesionek and 
Kiolemenoglou described similar enlarged cells and described them as ‘protozoan-like’. These 
were also found in the kidney of a still-born infant. Jesionek, in the same year, reported similar 
‘protozoan like’ cells in the lungs, kidneys and liver of the prematurely born fetuses. In 1907 
Löwenstein described cytoplasmic and nuclear inclusions in these protozoal-like cells, 
followed by a clear zone (Ho, 2008; Riley, 1997; Weller, 2000). In 1907, Goodpasture and 
Talbot used the term ‘cytomegalia’ to describe these abnormal cells, and they were in 
disagreement that the inclusion bodies were caused by a protozoan, but were unclear over what 
caused that cytopathology (Goodpasture E. W., 1921). In 1925, Von Glahn and Pappenheimer 
observed that cells infected with herpesviruses contained inclusion bodies, they suggested that 
cytomegalic cells were more likely caused by a virus rather than protozoa (von Glahn & 
Pappenheimer, 1925). Later, finding from Cole also supported that the formation of inclusion 
bodies are likely due to infection with viruses (Wyatt et al., 1950). Later other researchers 
agreed to a virus as the likely cause of the pathology of these cells, and this condition of 
unknown viral aetiology was termed  ‘generalised cytomegalic inclusion disease’ (Wyatt et al., 
1950). 
In the mid of the 1950s, three different laboratories reported that they isolated a virus from 
tissue cultures of human adenoid and salivary gland, and named these viruses AD169, Smith 
and Davis (Rowe et al., 1956; Smith, 1956). It was also called the ‘salivary gland virus’ and 
shortly thereafter Weller et. al. named it ‘cytomegalovirus’(CMV) (Craig et al., 1957). The 
isolation and propagation of the virus in cultures enabled further development of understanding 
of the nature of this virus, such as detection of virus protein, its life cycle and later its molecular 
pathogenesis. Recently, I together with colleagues cherished the talks held in a symposium in 
Germany with renowned international experts in celebrating the 60th anniversary of CMV 
isolation. At this meeting, they high-lighted the important work by Smith, who was a pioneer 
in this field and described the discovery of murine CMV, which allowed for later development 
of animal models to study the pathogenesis of CMV (Reddehase, 2015). 
 
1.2 Herpesviridae and its subfamilies 
Herpesviridae is one of the largest family of viruses. It consists of hundreds of different viruses, 
and they are extensively prevalent in nature. Most animal species have experienced at least one 
herpesvirus infection during their lifetime. These viruses are classified into the herpesviridae 
family, as they share similar features in virions architecture, conserved genomic segments, and 
upon infection they have similar biological properties (Roizmann et al., 1992). A recent 
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classification of new viruses is mostly based on the data obtained from nucleotide and amino 
acid sequence similarities (McGeoch et al., 2000). 
The general characteristics of a herpesviridae family are their linear double-stranded DNA 
(dsDNA) genetic code with a size ranging from 120 – 240 kbp that is enclosed by an 
icosahedral capsid (100 -130 nm external diameter). The capsid is made of 162 hollow centred 
capsomeres (12 pentons and 150 hexons) and is surrounded by an asymmetric and amorphous 
tegument protein layer, which is further surrounded by a host-derived lipid bilayer membrane 
called the envelope. The envelope is studded with viral and host transmembrane proteins on its 
surface, which will mediate binding and entry to the next target cell.  
 
The four most common biological properties shared among all herpesviridae include: 
1. Herpesviruses have their own enzymes involved in nucleic acid metabolism, DNA synthesis 
and protein processing such as helicases, DNA polymerases, primases and tymidine kinases – 
the number of enzymes may vary among deferent species. 
2. DNA synthesis and capsid assembly of all herpesviruses take place in the nucleus, and 
maturation of the virion occurs in the cytoplasm of the infected cells. 
3. The spread of new viral progeny occurs by lysis of the infected host cell, or by the release of 
intracellular vacuoles containing mature virions. 
4. Their unique ability to establish latency in their natural host, from which the virus can be 
reactivated. The host cell types in which they establish latency vary among the different viruses. 
For example, HSV-1 and -2 and VZV remain latent in neuronal cells of dorsal root ganglia 
(Hyman et al., 1983; Kramer et al., 2003). EBV latency is found in B-lymphocytes (Hurley & 
Thorley-Lawson, 1988) and HCMV establishes latency in myeloid lineage cells (Soderberg-
Naucler et al., 1997; Söderberg-Nauclér et al., 2001). 
Although all herpesviruses exhibit similar features, the number of open reading frames (ORF) 
in the genome varies considerably; from 70 – 250 (VZV - CMV). 
Based on their primary variations in biological properties such as host cell tropism, latency 
features, replication cycle and the differences in clinical manifestations, herpesviridae family 
members are further classified into three major subfamilies. i) Alphaherpesvirinae ii) 
Betaherpesvirinae and iii) Gammaherpesvirinae. The viruses of each sub-family have variable 
hosts including humans. Among the all known herpesviruses, there are nine viruses that are 
known to primarily infect humans. These nine viruses are also classified to the three different 
sub-families as mentioned above. According to the ICTV website, there are also some   
‘unassigned’ genera in all the three sub-families of herpesviruses (contains non-human), which 
consists of the viruses which needs to be classified / does not currently fit into any of the 
available sub-families. Hereafter, I will only discuss human herpesviruses and the biological 
characteristics of their sub-families. 
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i) Alphaherpesvirinae: There are three alpha herpesviruses that infect humans; HSV-1 and 
HSV-2, and (VZV). The replication cycle of these viruses is very short, about 12-18 h and the 
host cells lyses for the production of new viral progeny. They all establish a latent infection in 
sensory ganglia. 
ii) Betaherpesvirinae: This sub-family includes four human viruses; Human herpesvirus 5/ 
HHV5/ HCMV (Genera: Cytomegalovirus), HHV6A, HHV6B and HHV7 (Genera: 
Roseolovirus). Infected cells frequently become enlarged in size (cytomegalic cells) and can 
establish latent infection in lymphoreticular cells, secretory glands and bone marrow cells. In 
general, members of this sub-family are more complex than the alpha herpesviruses and have 
a long replication cycle (> 24 h). The infection progress slowly and may or may not result in 
cell lysis. 
iii) Gammaherpesvirinae: Members of this subfamily infect and replicate in lymphoblastoid 
cells such as T- and B- lymphocytes and also establish latency in these cells. They also infect 
and can cause a lytic infection in epithelioid/fibroblast cells. There are two human viruses in 
this subfamily; they are both considered to be oncogenic viruses; the EBV/HHV4, Genera: 
Lymphocryptovirus and KSHV/HHV8, Genera: Rhinovirus. EBV is associated with different 
types of lymphomas and KSHV with Kaposis sarcoma in AIDS patients. 
 
1.3 Genome and its organisation 
The HCMV genome consists of a linear dsDNA, the size of the genome ranges from 220 – 240 
kbp among the various strains that have been sequenced. The first complete HCMV genome 
was published in 1990 (Bankier et al., 1991; Chee et al., 1990), which is almost 14 years before 
the complete Human genome sequence was published (Schmutz et al., 2004). Since then, many 
researchers have sequenced various strains of HCMV; their different genomes are discussed in 
a recent review (Sijmons et al., 2014). To compare the complexity and variations of HCMV 
genome sequences, a low passage clinical strain, Merlin, is today considered as the reference 
genome (NCBI GenBank accession NC_006273.2). 
The HCMV genome is the largest of all human herpesvirus genomes, and seems to be the most 
complex of them. Analysis of genomes of different HCMV strains revealed about 165-252 
ORFs potentially encoding about 170 proteins (Dolan et al., 2004; Murphy et al., 2003). 
However, in a recent study, researchers used ribosomal profiling and transcripts analysis and 
found 751 unique translated ORFs in HCMV infected cells. The investigators suggested that 
HCMV has a much more complex coding capability than previously believed (Stern-Ginossar 
et al., 2012). Furthermore, HCMV also encodes for at least four polyadenylated long non-
coding RNAs and 26 microRNAs that carry out important functions during virus-host 
interactions and virus replication (www.mirbase.org Version-21) (for detailed miRNA 
description, please see chapter-III). 
In 2009, after the development of the next generation sequencing (NGS) technology, two 
variants of Towne and AD169 strains were identified (Bradley et al., 2009). For the analysis 
of the NGS data, a known genome sequence was used as a reference genome but for the 
investigation of the unknown/variations of the genomes this strategy was not useful. For 
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unknown or variants of viruses or organisms, a reference sequence independent assembly 
method (de novo assembly) has been developed. Since the last five years, the NGS technology 
has become user-friendly and affordable. Currently, the virus-pathogen resource genome 
database has 243 complete HCMV genome sequences including in vitro genetically modified 
strains (www.viprbrc.org).  
Organisation of the HCMV genome 
The sequencing analysis of the HCMV genome has revealed that it has a very complex 
organisation. Overall, the HCMV genome has two major segments called the Unique Long 
(UL) and Unique Short (US) segments. These two segments are joined with Internal Repeated 
Long segments (IRL) and Internal Repeated Short segments (IRS). These are flanked with 
Terminal Repeated Long segments named as TRL and Terminal Repeated Short segments 
(TRS). The IRL and IRS segment sequences are inverse to the sequences of TRL and TRS, 
respectively (Mocarski et al., 2007). Based on the organisation of the genome segments, the 
herpesvirus genomes are classified into A-F classes. The HCMV genome is classified as an E 
genome (Roizman & Pellett, 2001) Fig. 1. 
The HCMV gene annotations are based on their location in the respective genome segments; 
UL, US, IRL, IRS, TRL and TRS and their positioning in the genome. For example; UL112, 
US28, etc. 
  
Figure. 1 Classes of herpesvirus genome structures (not to scale) defined by 
Roizman and Pellett (2001). Arrows = Orientations of repeats; Horizontal lines = 
Unique regions; Rectangles = Repeat regions. 
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1.4 Infected Cells Produce Virions and Defective Particles  
Definition of a virion 
A complete virus particle that consists of an RNA or DNA core with a protein coat or 
sometimes with external envelopes representing the extracellular infective form of a virus. 
As described in the Herpesviridae section above, the HCMV virion architecture is similar to 
that of other herpesvirus members. The particle is spherical, about 230 nm in diameter, and 
contains a linear dsDNA enclosed in an icosahedral nucleocapsid of about 100 nm in diameter. 
A thick tegument layer further surrounds the nucleocapsid; a host-derived lipid bilayer called 
the envelope covers the tegument layer. The membrane of the envelope is studded with viral 
and host encoded transmembrane proteins; these proteins are exposed on the surface of the 
envelope, reviewed in (Kalejta, 2008) with the main function to target and gain entry to new 
cells. 
 
Capsid 
The capsid is innermost core layer of a virion particle (also called nucleo-capsid), which 
contains and protects the genome. The shape of the capsid is icosahedral and made of 162 
hollow centered capsomeres (12 pentons and 150 hexons). The major function of the capsid 
during the infection is to protect the DNA and to deliver the genomic code to the nucleus of 
Figure. 2 HCMV infection produces virions and dense bodies (DBs) and Non-
infectious enveloped particles (NIEPs). Virions and NIEPs are similar in size, about 
250 nm, whereas the DB are bigger in size, about 250-600 nm. Virions are the fully 
mature infectious particles, NIEPs and DBs are considered non-infectious. DBs are 
denser than virions and NIEPs. 
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the host cell. There are three types of HCMV capsids: A-capsid (only capsid shell), -B capsid 
(capsid shell and assembled proteins) and –C capsid (a mature capsid containing the viral 
genome). These three capsids represent three different stages of capsid maturation that takes 
place in the nucleus of infected cells (Gibson, 1996). Capsid-A and Capsid-B can also proceed 
to envelopment; they then form immature virions that are defective (Irmiere & Gibson, 1985). 
The capsid is made of at least five proteins, i) Major Capsid Protein (UL86), ii) Minor Capsid 
Protein (UL85), iii) Smallest Capsid Protein (SCP, UL48- 49), iv) Assembly protein 
(Fragments of UL80) and v) Minor Capsid Binding Protein (MCP, UL46), as reviewed in 
(Gibson, 2008). 
Tegument 
The widest layer within the virion structure is the tegument layer, which closely surrounds the 
capsid; it is believed to be important to anchor the envelope to the tegumented capsid. Electron 
microscopy studies show that the tegument layer is amorphous and likely not well structured. 
The tegument layer contains the largest amount of proteins that are constituting the entire 
virion. Most of these tegument proteins are phosphorylated, thus, often designated with a prefix 
‘pp’. The functions of most of them are still unknown. The most well studied tegument proteins 
so far are pp65/ppUL83, pp71/ppUL82, pp150/pUL32 and pp28/pUL99 (Varnum et al., 2004). 
These proteins play major roles during virus entry (un-coating), intracellular capsid 
transportation and assembly.  Studies of pp65 deleted viruses show that lack of pp65 led to a 
growth modified viral phenotype that can replicate in vitro but as pp65 is essential for the 
formation of dense bodies (Schmolke et al., 1995). Pp28 is a necessary protein for the assembly 
and it’s known to be highly immunogenic (Meyer et al., 1988). The Pp71 protein trans-activates 
the IE gene, which is essential for replication. In the tegument, many host encoded proteins 
were also found (Varnum et al., 2004). The formation of the tegument layer and incorporation 
of these proteins are not fully elucidated yet. Along with viral and host proteins, there are also 
viral and host encoded RNAs present in the tegument layer, which suggest that they may play 
a role in HCMV biology; but this topic needs further in-depth investigations (see study-II, for 
more detailed description), reviewed in (Kalejta, 2008; Tomtishen, 2012). 
Envelope 
The envelope is a lipid bilayer, which surrounds the tegument layer and keeps the entire virion 
intact. It interacts with the host cell membrane on target cells and thereby plays a major role 
during virus attachment and entry. HCMV and host encoded transmembrane glycoproteins are 
studded into the membrane and decorate the particle. The viral glycoproteins gpUL55 (gB), 
gpUL73 (gN), gpUL74 (gO), gpUL75 (gH), UL100 (gM), gpUL115 (gL) and the pentameric 
complex consisting of gL, gH and UL128-131, are known to play important roles in virus entry 
(see section below), cell-to-cell spread and virion maturation (Ryckman et al., 2008). 
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Defective HCMV particles 
During a lytic infection, HCMV along with mature virions also produces the two types of 
defective particles, the dense bodies (DBs) and non-infectious enveloped particles (NIEPs) 
(Fig. 2). Several methods have been developed to isolate these particles from one another and 
also from cell culture medium (Irmiere & Gibson, 1983; Stinski, 1976; Talbot & Almeida, 
1977b). Different densities of different HCMV particle types allows for their separation with 
ultracentrifugation techniques. NIEPs are of same size as virions but does not contain viral 
genome, and are this less dense than virions (Roby & Gibson, 1986). The DBs are larger in 
size compared to with virions and NIEPs, and ranges from approx. 250-600 nm in diameter; 
they are also denser than virions and NIEPs. DBs contain most of the structural proteins as are 
present in mature virions. However, although they contain capsid proteins, these are not 
organized into a capsid shell and hence no viral genome can be packed into a protective capsid. 
Further in depth analysis of protein and phosphoprotein contents of virions, demonstrates that 
DBs and NIEPs have many viral as well as host proteins packaged into the particles (Stinski, 
1976; Varnum et al., 2004) into the particles. 
Several investigators also reported that RNA transcripts are also packaged within different 
particles of HCMV and can also deliver these RNA into target cells (Greijer et al., 2000; 
Prichard et al., 1998a; Sarcinella et al., 2004; Terhune et al., 2004). The presence of the RNA 
transcripts in the particles and their delivery to target cells have also been observed by other 
members of the herpesvirus family, as reviewed in (Amen & Griffiths, 2011b). However, still 
no high throughput methods have been applied for screening of all RNA molecules present in 
those particles. It has been suggested that particles package RNA non-specifically and the 
proportion to the RNAs present in the infected cells, will be reflected in the viral particles 
(Terhune et al., 2004).  
DBs can induce both humoral and cellular immune responses and can produce neutralizing 
antibodies against the virus (Cayatte et al., 2013; Pepperl et al., 2000). Several animal 
experiments suggested that DBs could be used as vaccines but yet the impact of the RNAs 
delivered by these particles warrants further investigations. Therefore, another promising 
strategy is being evaluated: DBs can be produced with recombinant-antigens and these were 
shown to induce T-cell responses to the recombined antigens without an adjuvant. This strategy 
is currently under development as a promising HCMV vaccine (Becke et al., 2010; Mersseman 
et al., 2008; Pepperl-Klindworth et al., 2003).  
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1.5 Entry, Replication and Virus Assembly 
Entry 
Viruses have to deliver the viral genome to its host cell to begin the infection. First the viral 
surface proteins and the host cell membrane have to interact and facilitate entry to occur. 
HCMV enters almost all cell types, results in productive infection in most of them such as 
epithelial, endothelial and smooth muscle cells but in monocytes the infection will remain 
latent/non-productive. Monocytes have to differentiate into macrophages or dendritic cells 
before the virus can replicate and produce new virus particles (Ibanez et al., 1991). This 
Figure 3 Overview of the human cytomegalovirus life cycle. (A) Virions enter the cell 
through interaction with cellular receptors. Tegument and capsid proteins are delivered to 
the cytoplasm. (B) The capsid travels to the nucleus, then the genome is delivered and 
circularized. Tegument proteins regulate host cell responses and initiate the temporal 
cascade of the expression of viral immediate early (IE) genes, followed by delayed early 
(DE) genes, which initiate viral genome replication, and late (L) genes. (C) Late gene 
expression initiates capsid assembly in the nucleus, followed by nuclear egress to the 
cytosol. Capsids associate with tegument proteins in the cytoplasm and are trafficked to the 
viral assembly complex (AC) that contains components of the endoplasmic reticulum (ER), 
Golgi apparatus, and endosomal machinery. The capsids further acquire tegument and viral 
envelope by budding into intracellular vesicles at the AC. (D) Enveloped infectious 
particles are released along with non-infectious dense bodies. Figure and figure legends are 
adapted from (Jean Beltran & Cristea, 2014) and modified. 
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indicates that HCMV enters the cells using various cellular receptors or that a common receptor 
is present on all cell types. 
The entry process involves three major steps i) Attachment to the surface of the host cell ii) 
Interaction with entry receptors at the host cell membrane iii) Internalization of the particle  or  
fusion of the viral envelope with the cell membrane (this depends on cell type for HCMV).  
HCMV encodes for at least 57 glycoproteins among which 14 have been biochemically proven 
to be the structural components of the virion. Only eight of these have been found to be present 
in the HCMV envelope, and their functions are not yet fully elucidated (Britt et al., 2004). 
HCMV-gB mediates attachment to cells via binding to cellular receptors including heparan 
sulphate proteoglycan (Jones et al., 2004), integrins (Feire et al., 2004) and EGFR (Wang et 
al., 2003) to promote the entry process. HCMV gH interacts with integrin αVβ3 and act as a 
co-receptor (Krummenacher et al., 2013). The heparan sulphate proteoglycan molecule allows 
the HCMV particle to attach closer to the cell membrane where viral glycoproteins bind to 
more specific receptors. This is mediated by gB and gH or its complexes (Compton et al., 1993; 
Luganini et al., 2010). 
Several other viral protein complexes can also mediate the entry process; a homodimer of gB 
called gC-I, and a hetero dimer composed of gM and gN that form gC-II and a heterotrimer of 
gH, gL and gO that forms the gC-III complex (Boyle & Compton, 1998; Huber & Compton, 
1997; Li et al., 1997). HCMV has two different entry routes in different cell types. In 
fibroblasts, virus entry is mediated by viral envelope glycoprotein complexes gH/gL-gB and 
gH/gL/gO via direct fusion at the plasma membrane (Kabanova et al., 2016; Wille et al., 2010). 
Annexin-II (Pietropaolo & Compton, 1997) and Aminopeptidase N (CD13) (Söderberg et al., 
1993) serves as receptors to promote entry at the plasma membrane, however none of these 
receptors are essential for the entry and replication (Giugni et al., 1996; Pietropaolo & 
Compton, 1997), as several other receptors can also act to mediate entry. 
In endothelial and epithelial cells, monocyte/macrophages and dendritic cells, the viral 
pentameric complex gH/gL/UL128/UL130/UL131A is essential to mediate receptor-mediated 
endocytosis (Vanarsdall & Johnson, 2012). The virus then fuses with the endosomal membrane 
to release the capsid to the cytoplasm. Post entry, the dissociation of the tegument will take 
place and the capsid will be directed from the cytoplasm to the nuclear pore to deliver the DNA 
to the nucleus, this process also mediated by many proteins of the tegument. The viral receptor 
that mediates entry through receptor mediated endocytosis has been searched for during 
decades. Virus binding to EGFR, PDGF, and integrins result in activation of intracellular 
signalling processes involving activation of src and paxillin that appears to be essential for this 
process (Nogalski et al., 2013). Our group recently discovered that the pentameric complex 
specifically interacts with endothelin receptor B (ETBR) and this results in similar activation 
cascade resulting in a downstream activation of cavelolin I that mediates the formation of the 
virus containing endosome. One ETBR blocker that are already approved for treatment of an 
unrelated disease, pulmonary hypertension (Macitentan), blocks HCMV infection in 
endothelial cells, epithelial cells and macrophages by more than 90% in vitro. ETBR thus 
seems to be a long searched for HCMV receptor on these cell types, and this new knowledge 
may open for new strategies for antiviral therapy. 
 20 
Lytic replication 
In general, HCMV infection of cells leads to an active replication of the viral genome and 
production of viral progeny that are released by lysis of the infected cells, called the lytic phase. 
The replication of viral DNA is key to produce more viruses during the course of infection. 
HCMV DNA replication is highly regulated and dependent on the expression of certain viral 
proteins. Once viral DNA is delivered into the host cell nucleus, gene expression takes place 
in three stages; first immediate early genes (IE) are expressed, followed by early genes (E) and 
late genes (L). The IE gene products act as transcription factors and will regulate expression of 
the E and L genes. The host cell transcription and translation machineries will be utilized for 
producing IE proteins, which are produced within 1-4 hours following initiation of the 
infection. IE proteins acts as trans-activators for gene expression (of both viral and cellular 
genes) and are therefore essential for production of E and L proteins (Fortunato & Spector, 
1999). The E proteins mostly interfere with the host proteins, and also affect the transcriptional 
and replication machinery for viral protein production.  
HCMV encodes its own proteins to regulate the replication machinery such as a DNA-
polymerase (UL54) and DNA primase (UL70) to sustain an efficient production of new virus 
progeny (Van Damme & Van Loock, 2014). The L proteins are mainly structural components 
of the virions and also include proteins essential for virion assembly and egress. The HCMV 
genome contains a cis-acting lytic origin of DNA replication (OriLyt) element that initiates the 
bidirectional DNA replication model followed by a rolling circle mechanism to generate viral 
DNA molecules to be incorporated into new virus particles (Lehman & Boehmer, 1999; Pari, 
2008). The entire replication cycle for HCMV is rather long and it takes approximately 72 h 
before new virions are mature and ready to infect the next cells either by release from the 
infected cells or by spread via cell-to-cell mechanisms (Gibson, 2006). During the latent phase 
of infection no replication will take place and only selected gene transcription and translation 
of viral proteins take place. Once in a while when the conditions are favourable, HCMV may 
get reactivated and a usual lytic replication will develop and spread new viral progeny (for 
latency, see section below).  
Virus assembly 
After the pre-capsid assembly step, the newly made DNA is inserted into an immature B capsid 
and become a fully matured C capsid. This DNA packed capsid, egresses from the nucleus 
through the nuclear membrane, by an envelopment and de-envelopment process (Muranyi et 
al., 2002). It is unclear how tegumentation takes place, but as all capsids in the cytoplasm are 
tegumented, while none are in the nucleus, this process must take place through or rapidly after 
nuclear egress. The tegumented particle then egresses to cytoplasmic vacuoles for final 
envelopment. Mature particles are released by transport of Rab3 secretory vesicles to be 
released by fusion of the vacuole with the plasma membrane, or through cell lysis (Homman-
Loudiyi et al., 2003).  
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1.6 Latency and Reactivation 
The latency phase can be defined as an ability of the virus genome to persist and remain 
dormant in infected cells from where the virus can get reactivated and produce virus when the 
host cell environment favours such process. Latency allows the virus to establish a persistent 
infection in the host, without destroying the host cells. The ability to establish latency is one of 
the key biological properties of herpesviruses. In healthy individuals (an immune competent 
host) primary HCMV infection is mostly asymptomatic and results in a latent and persistent 
infection. 
In 1985, for the first time HCMV DNA was detected in PBMCs by the in situ hybridization 
technique (Schrier et al., 1985) and later several others groups  confirmed the presence of 
HCMV in blood using PCR methods (Bevan et al., 1991; Stanier et al., 1989). Further studies 
confirmed that the adherent monocytes/macrophages are major cell types which harbours the 
HCMV latent infection, rather than B-cells and T-cells. (Taylor-Wiedeman et al., 1991). It is 
now established that the bone marrow derived CD34+ myeloid progenitor cells (Mendelson et 
al., 1996; Sindre et al., 1996) and their derivative CD14+ monocytes harbour the latent 
infection (Soderberg-Naucler et al., 1997), and during the latency phase, the virus genome was 
localized as an episome   (Bolovan-Fritts et al., 1999).  However T-cells and B cells also both 
derived from the CD34+ myeloid lineage cannot maintain the latent HCMV infection. The 
cellular transcription factor GATA-2 is a key player in differentiation of myeloid cells to 
monocytes, and is proposed to be important in maintaining latency of the viral genome in 
myeloid lineage cells (see below). Whether endothelial progenitor cells or mature endothelial 
cells also carry the latent infection is not clear. The virus is found in endothelial cells in healthy 
subjects, but so far no studies demonstrate that it can be reactivated from latency in this cell 
type. In in vitro studies, latently infected monocytes have to differentiate into macrophages 
(Soderberg-Naucler et al., 1997) or dendritic cells (Reeves et al., 2005) in order to induce 
reactivation of HCMV; the virus then enters a lytic phase. This phenomenon can cause severe 
disease in immunocompromised patients such as stem cell or organ transplant patients. 
 
Mechanisms of latency and reactivation 
In general, the interplay between the host and virus encoded proteins are the key to optimize 
host cells to maintain HCMV in a latent state of infection or allow the virus to enter the lytic 
phase. The mechanisms behind the latency state of a natural infection are beginning to be 
understood. 
MIE act as a trans-activator for the transcription of most HCMV encoded genes, and is essential 
for replication of the virus and to proceed to the lytic phase of infection. During latency, the 
MIE promoter is transcriptionally repressed by cellular factors (Ets2 Repressor Factor, HP1) 
(Bain et al., 2003; Ghazal et al., 1990; Murphy et al., 2002; Wright et al., 2005). The chromatin 
around the MIE gene is also repressed by these factors and results in inhibition of the lytic cycle 
phase and plays a role in maintenance of the latent phase of infection. Early studies suggested 
that no transcription of the HCMV genome takes place during latency.  Later studies noted that 
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a limited set of genes were transcribed also during latency. Cell culture models studying 
experimental infection of CD34+ positive cells, showed expression of latency associated 
transcripts and production of some proteins. The latency associated gene product UL138 is 
required for establishment of viral latency and maintenance. The HCMV-LUNA and UL138 
are produced during the HCMV latency and lytic infection (Bego et al., 2005), and activates  
CD4+ T cells and this leads to production of IL-10 and IFN-γ; one with immunosuppressive 
and one with immuno-activating effects that favours replication and reactivation of latent 
HCMV. The produced IFN-γ can promote macrophage differentiation, which could lead to 
reactivation and enhanced replication of HCMV (Jenkins et al., 2008). UL138 also down 
regulates the multidrug resistance protein-1, MRP1 (Weekes et al., 2013), which can lead to 
reduced cellular leukotriene C4 export, which may prevent DCs to reach lymph nodes, and 
impair an HCMV specific immune response (Robbiani et al., 2000). Another strategy 
employed by HCMV to suppress the immune system during viral latency is provided by 
expression of the UL111a gene; it encodes a functional IL-10 homologue with powerful 
immunosuppressive effects. During the latent phase of infection UL111a undergoes alternative 
splicing, which leads to expression of a latency associated cmvIL-10 transcript, which produces 
a protein that mimics the function of the human immunosuppressive cytokine IL-10. This 
favours the infected cells not to be recognized by the immune system and to avoid clearance 
(Jenkins et al., 2008). Furthermore, US28 and UL144 are also expressed during latency and 
manipulate the cellular environment and redirect the immune response or block immune 
recognition (Beisser et al., 2001; Goodrum et al., 2007b; Poole et al., 2013).  
When HCMV infects differentiated cells, it permits viral replication while in some 
undifferentiated cells it remains in a non-permissive state (Sissons et al., 2002). For example, 
macrophages allow for an active infection, while monocytes do not. Latently infected HCMV 
is only reactivated when monocytes are differentiated into macrophages or dendritic cells, in 
which the virus can replicate. Therefore, the expression of latent genes is most probably 
directed by the cellular transcriptional milieu. Recent in vitro studies in infected CD34+ 
progenitor cells found that HCMV down regulates cellular miRNA miR-92a, which leads to 
upregulation of the cellular transcription factor GATA-2 (Poole et al., 2011), and  increased 
expression of cellular IL-10 (Mason et al., 2012). GATA-2 is known to play an important role 
in myeloid cell differentiation, suggesting that GATA-2 might be a key regulator for the 
establishment of the HCMV latency.  
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1.7 Epidemiology and Clinical Features  
 
 
The HCMV seroprevalence ranges from 45- 100% worldwide, and depends on socioeconmial 
status and/or geography location (Cannon et al., 2010).  HCMV can be transmitted via various 
routes, which includes horizontal close personal contact, vertical transmission from mother to 
child, also through other bodily fluids via breast feeding, urine, blood transfusion, stem cell 
and organ transplantation, and sexual contact. HCMV can infect humans at any age. 
Approximately 30-40% of children are infected with this virus by one year of age (Asanuma 
et al., 1996). HCMV primary infection of pregnant women are at increased risk of transmitting 
the virus to the fetus and causing infection with a substantial risk of birth defects (Syggelou et 
al., 2010). 
In most children, the congenital infection is asymptomatic at birth. The prevalence of infection 
in new-borns, ranges from 0.2% - 2.5 % of all births. Only about 10-15% of these demonstrate 
clinical symptoms and only few present with congenital abnormalities including hearing loss, 
mental retardation and visual impairment. The most common clinical signs in the congenitally 
infected children are anaemia, thrombocytopenia, petechia, jaundice and hepatosplenomegaly. 
Further clinical manifestations include growth retardation, lethargy, seizures, and 
microcephaly (Syggelou et al., 2010). 
HCMV infection in healthy, immunocompetent hosts is generally asymptomatic or present 
with symptoms of upper respiratory tract infection or more severe mononucleosis. Common 
symptoms may also include headache, a sore throat, fever, malaise, lethargy, splenomegaly and 
Figure 1. Worldwide HCMV seroprevalence rates in adults. Studies of adults aged 
16–50 years published between 2005 and 2015 from Australia, Belgium, Brazil, 
Canada, Cambodia, Chile, China, Finland, France, Gambia, Germany, Ghana, India, 
Israel, Italy, Japan, Kenya, Mexico, Nigeria, Panama, South Africa, Spain, Sweden, 
Taiwan, Tanzania, Turkey, UK, USA, Zambia, and Zimbabwe. Figure and Figure 
legend is adapted from (Adland et al., 2015) 
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lymphadenopathy (Eddleston et al., 1997). In contrast to the relative mild infection it causes in 
healthy people, this virus can cause life-threatening disease in immunocompromised patients.   
In organ transplant patients, HCMV infection is also associated with acute and chronic rejection 
and other post-transplant related complications (Linares et al., 2011). Significant morbidity and 
mortality has been reported in organ or stem cell transplant patients as well as AIDS patients. 
In immunocompromised patients HCMV infection can be found in various organs in the body; 
it can cause retinitis, pneumonitis, gastrointestinal disease and rarely also encephalitis 
(Ljungman, 1996). Increasing evidence also demonstrates a significant correlation between 
HCMV sero-positivity and atherosclerosis and increased cardiovascular mortality (Sorlie et al., 
2000). HCMV has also been associated with rheumatoid arthritis (Rothe et al., 2016), 
inflammatory bowel diseases (Dimitroulia et al., 2006), Sjögren´s syndrome (Shillitoe et al., 
1982) and Systemic Lupus Erythematosus (Perez-Mercado & Vila-Perez, 2010). These studies 
imply that there is a link between HCMV infection and autoimmune diseases. As stated above, 
HCMV can be reactivated by inflammation, and inflammation thrives viral replication. 
Inflammation and production of for example IL-1, IL-6 and TNF alpha produced from M1 type 
of macrophages may promote viral replication (Chan et al., 2008). Whether the presence of 
HCMV is an epiphenomenon or driver of inflammatory diseases warrant further investigation. 
Association of HCMV with various cancer types has been extensively discussed in the Chapter-
II. 
 
1.8 Immune Responses to HCMV Infection 
 
HCMV infection induces an innate immune response, which is followed by adaptive and cell 
mediated responses. Regardless of a robust host immune response, a primary infection will lead 
to a persistent and latent infection, from which it can reactivate whenever the environment 
favours (Jackson et al., 2011). The immune response to HCMV may protect the infected 
individual from symptomatic recurrent infections, but does not protect the host from being re 
infected, as several strains of HCMV have been found in the same individual (Chou, 1989). 
HCMV has also developed multiple sophisticated strategies to evade the host immune system, 
and remain dormant.  
HCMV and NK cell response 
Rolf Kiessling and colleagues discovered NK cells at the Karolinska Institutet in 1970. They 
play a major role in the innate immune system, especially in viral and parasitic infections. NK 
cells also help driving the adaptive immunity. In 1989, recurrent HCMV associated disease 
was noticed in a few patients who had NK cell defects, which led to the understanding of the 
importance of NK cells in immune responses against viruses (Biron et al., 1989). NK cells 
patrol tissues and can become activated by a balance of numerous activating and inhibiting cell 
surface ligands. The first described activation pathway was “the missing self-hypothesis”, 
described by Kärre et. al. at the Karolinska Institutet in 1981. They described that NK cells 
became activated by the loss of MHC class I molecules on the target cells. Other ligands such 
as MHC class I related chain A or B (MICA, MICB) that are expressed on stressed cells as well 
as infected and transformed tumour cells activate NK cells (Arase et al., 2002). Recent 
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investigations found that MICA*008 and MICB are downregulated by the HCMV UL9 and 
miRNA miR-UL112 in infected cells, which results in escape of recognition by the NK cells 
(Seidel et al., 2015; Stern-Ginossar et al., 2008).  HCMV gB and gH receptors are recognized 
by the TLR2 receptors that initiate production of pro-inflammatory cytokines and interferons, 
which subsequently results in activation of NK cells via NFkB (Boehme et al., 2006). The 
HCMV-UL40 protein induces HLA-E expression and inhibits the functions of NK cell via 
CD9/NKG2 inhibitory receptor (Tomasec et al., 2000; Ulbrecht et al., 2000). HCMV infection 
induces the expression of ligands ULBP1 and 2, these ligands activate the NK-cells via the 
NKG2D receptor. HCMV UL16 protein binds to ULBPs and prevent the recognition by NK 
cells, also limiting the expression of these ULBPs on the cell surface, which results in decreased 
susceptibility to NK cells (Rölle et al., 2003). 
Cell mediated immunity to HCMV 
In cell mediated immunity, CD8+ T cells are the major key players involved in the control of 
HCMV infections. The CD8+ T cells can recognize and kill the infected cells via recognizing 
the viral proteins presented on their surface by MHC-I molecules. Both pp65 and IE72 peptides 
were shown to be recognized by CD8+ T cells and induced an immune response able to kill 
infected cells (Kern et al., 2002; Kern et al., 1999). The diversity of HCMV peptides that the 
immune system can recognize is very broad (Portland data Picker). The immune response 
against HCMV is remarkably strong and increases with the age; in elderly persons it may 
constitute approximately 50% of the CD8+ T-cell repertoire (Moss & Khan, 2004). In murine 
bone marrow transplant models, the removal of reconstituted CD8+ T cells leads to lethal 
infection whereas reconstituting the bone marrow in immunocompromised mice prevents 
CMV disease (Polic et al., 1998). Similarly, in humans, a strong correlation was found between 
the recovery of the CD8+ T cell population and protection from HCMV disease (Cwynarski et 
al., 2001). Patients who received ex vivo expanded CD8+ T cells were protected from HCMV 
primary and recurrent infections. The function of infused HCMV specific CD8+ T cells was 
reliant on the presence of HCMV-specific CD4+ cells. These observations suggest that CD4+ 
helper T cells might be vital for effective CD8+ T cell responses (Einsele et al., 2002). Indeed, 
CD4 +T cells also play an essential role in the control of HCMV infections. CD4+ T cells 
recognise viral peptides presented via MHC-II molecules on the antigen presenting cells (Le 
Roy et al., 2002). HCMV specific CD4+ T cells can also act as effectors directly to virus 
infected cells (Gamadia et al., 2004; Rentenaar et al., 2000). The gamma delta T-cells represent 
a minor subset of T cells that are also expanded during HCMV infections, and these cells have 
the ability to mediate cytotoxicity of infected cells by yet unknown ligand/receptor interactions 
(Halary et al., 2005). 
  
Humoral immunity /Antibody responses against HCMV 
The humoral immune response controls HCMV infection via specific antibodies, this helps the 
host to eradicate the virus via phagocytic cells or antibody-dependent cell-mediated 
cytotoxicity (ADCC) by NK cells. The antibodies can also be neutralizing and prevent infection 
of new cells as they bind to viral glycoproteins that need to interact with cellular receptors for 
entry. The humoral immune response helps in reducing the infection burden and limits viral 
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spread (Landini et al., 1988). The antibody response is directed towards both structural and 
non-structural proteins. 
 
1.9 HCMV Diagnosis and Virological Methods 
For the diagnosis of the HCMV infections in humans, several laboratory investigations are 
used. These include: 
Antigenemia assay 
For a long time this was one of the most widely used diagnostic assays for detection of HCMV 
infected cells in blood samples. Isolated leukocytes in cytospots or smears were subjected to 
immunofluorescence staining using antibodies against HCMVs tegument protein pp65 and 
followed by fluorophore conjugated secondary antibodies. The method detects pp65 in 
granulocytes, but this does not reflect virus producing cells. Pp65 will be delivered by the virus 
particle to granulocytes, while HCMV does not replicate in in these cells. This method is very 
simple and relatively cheap to perform. The pp65-positive leukocytes correlates with risk of 
disease, but the threshold number that predicts disease varies with the clinical setting (Boeckh 
& Boivin, 1998). In research laboratories, this immunostaining method is also is used for 
detection of HCMV in various in vitro infected cells using various HCMV specific antibodies 
(see study-IV & V). In study-III, a similar technique was used; instead of fluorophore 
secondary antibodies HRP-conjugated secondary antibodies were used and later developed 
with DAB to visualize the staining, this method is called Immunocytochemistry. 
Serology/ ELISA 
Investigation of the presence of HCMV specific IgG or IgM antibodies in the serum/plasma of 
patients is performed with ELISA tests. The HCMV IgG antibodies determine if the infection 
occurred or not; to know the status of the active infection or a very recent infection, HCMV 
IgM antibodies has to be investigated. Furthermore, for the acute HCMV infections an avidity 
test for HCMV IgG antibody can also give guidance of a recent or old infection. A recent 
infection gives less IgG avidity and can improve the accuracy of the ELISA test, as of time the 
infection progresses, the avidity of antibodies produced will increase (Grangeot-Keros et al., 
1997). It has been reported that some IgM antibodies lack HCMV specificity, and may give 
false positive results (Edward S. Mocarski et al., 2007). A neutralization assay can also be a 
reliable method for differentiation of active or non-primary infections (Eggers et al., 2000). In 
study-I we determined the prevalence of HCMV IgG and IgM antibodies in plasma of patients 
and healthy blood donors using kits from the Karolinska University virology laboratory or from 
Hoffmann La Roche Ltd. 
Virus culture 
Isolation of HCMV from clinical specimens is still a gold standard method but can take 3-6 
days or even a few weeks, dependent on the number of copies present in the specimen. The 
collected clinical specimen is co-cultured with fibroblast and followed by identification of the 
formation of a cytopathic effect / or a plaque, with a typical HCMV characteristic. The time 
for detection of HCMV can be shortened by combining the method for ocular detection of viral 
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plaques with immunostaining for the HCMV IE protein (Gleaves et al., 1984). As this method 
takes a lot of time and is laborious for routine clinical laboratories, most labs prefer the PCR 
method to detect HCMV DNA in blood or plasma (see below). In our study-I we isolated 
HCMV from clinical specimens. Sometime it can be challenging to isolate one particular virus 
from multiple viruses in cultures, in those cases each plaque isolated will be grown in a separate 
tissue culture flask. Once the desired virus isolate is obtained, later it can be used for 
propagation of more virus. 
PCR 
Today, most clinical laboratories used different PCR based methods to detect viral DNA copies 
in blood or plasma. As this method is sensitive, highly specific and most importantly rapid and 
quantitative, is has recently has been automated in many laboratories to process multiple 
samples (Gimeno et al., 2008). We have used different PCR methods in all the studies reported 
in this thesis. 
1.1 Treatment of HCMV Infection 
HCMV diseases can be treated with antiviral drugs, there are only five licensed drugs that are 
available today; ganciclovir, valganciclovir, foscarnet, cidofovir and fomivirsen. Except 
formivirsen, all other drugs are directly or indirectly targets the viral DNA polymerase UL54. 
Furthermore, all of these drugs have side-effects and may result in drug resistance (Mercorelli 
et al., 2011b). 
Ganciclovir (GCV) and Valganclovir (VGV) 
GCV was the first antiviral drug available for the treatment of HCMV infection, GCV is still 
the drug of choice. VGV is a pro-drug of GCV and available as enteral formulation, which 
rapidly metabolize to the active form in the liver and intestinal wall (Biron, 2006). GCV is 
available in intravenous formulation and also as a sustained-release intraocular implant.  GCV 
is an acyclic nucleoside analogue of 2′-deoxyguanosine, it gets incorporated instead of the 
nucleotides and inhibits viral DNA synthesis. The GCV has to be phosphorylated by the UL 
97 viral protein kinase to become biologically active in its  triphosphate form (Littler et al., 
1992). GCV resistance have been found in patients infected with HCMV strains containing 
mutations in the UL97 gene or the DNA polymerase gene (UL54) (Gilbert & Boivin, 2005). 
Haematological abnormalities (primarily neutropenia, anemia, and thrombocytopenia) as we 
as toxicity effects on the liver and kidney are the major side-effects  (Markham & Faulds, 
1994). 
Foscarnet 
This drug is manufactured as intravenous formulation. Foscarnet is used for those who cannot 
be treated with GCV due to dose-limiting neutropenia or leucopenia, or due to resistance to 
GCV (Razonable et al., 2004). Foscarnet is a pyrophosphate analogue, which also inhibits viral 
DNA polymerase and does not require enzyme activation after intake (Mercorelli et al., 2011a). 
Administration requires slow infusion and extensive pre-hydration, and monitoring of serum 
creatinine levels due to its potential nephrotoxicity as a side-effect (Naesens & De Clercq, 
2001). 
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Cidofovir 
Cidofovir is used only as a second line therapy, due to its side-effects.  Cidofovir has low oral 
bioavailability and is only produced as intravenous formulation. Cidofovir is an acyclic 
nucleoside phosphonate analogue. It becomes activated by the by cellular kinases, causes 
premature termination in viral DNA synthesis and inhibits the viral DNA polymerase (De 
Clercq & Holy, 2005). It has longer intracellular half time, which allows effective treatment 
even by irregular dosage (Aduma et al., 1995). The major side effects are renal toxicity, 
neutropenia, and electrolyte imbalance. Furthermore, in preclinical studies it has been shown 
to be teratogenic and carcinogenic (Lea & Bryson, 1996).  
Fomivirsen 
This drug is available as an intravitreal formulation, used for treating HCMV retinitis in 
immunocompromised patients, mostly HIV patients. It acts as an anti-sense RNA inhibitor (5'-
GCG TTT GCT CTT CTT CTT GCG-3') with phosphorothioate linkage to protect it from 
degradation; it binds complementary to HCMV IE86 RNA and inhibits translation. IE86 
proteins are essential for the production of early and late proteins and also essential for 
replication of the virus. It has a half-life of approximately 55 hours, which allows infrequent 
dosage, and due to its intraocular administration, it has no systemic effects during treatment 
(Geary et al., 2002). 
Novel drugs against HCMV infection 
As described earlier, most anti-HCMV drugs have the side-effects or due to its teratogenic 
effects they can’t be used for pregnant women or congenitally infected patients. In some cases 
however patients have been treated with acyclovir for congentical infection in utero and GCV 
post birth. Importantly, patients with GCV resistant infections need new therapy options. 
Discovery of new and less toxic anti HCMV drugs with alternative mechanisms of action may 
be helpful for present or for the future generations to come (Mercorelli et al., 2011b). 
Currently there are three new drugs are in preclinical studies. 
Maribavir is an inhibitor of HCMV UL97 kinase, an important molecule that digest the nuclear 
lamins. Inhibiting the UL97, prevent the maturation of capsids to egress from the nucleus to 
cytoplasm (Prichard, 2009). It has undergone phase-II trial and in phase-III it failed. Further, it 
can’t be used with GCV due to its antagonizing effect on the drug (Emery et al., 2000; Marty 
et al., 2011). 
Brincidofovir is a lipid prodrug of Cidofovir. It has no renal toxicity compared cidofovir, 
instead it has certain gastrointestinal toxicity, manifested as diarrhea (Marty et al., 2013). This 
drug also failed in its phase-III (Marty et al., 2016). 
 Letermovir has a unique mechanism of action among other anti-CMV drugs, it inhibits the 
viral terminase. When viral DNA  packaged into the capsid, terminase cuts the DNA  (Bogner, 
2002). 
Our group recently identified the ETBR blocker Macitentan to be a potential future treatment 
option for HCMV. This drug is presently in use for treatment of patients with pulmonary 
hypertension and blocks HCMV infection in vitro by interfering with receptor binding, 
signalling and transcription of CMV IE proteins (Bruderer et al., 2012).           
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Table 1. Anti HCMV drugs and treatment parameters.  
Generic  
(Trade Name)  
Route Usual Adult Dose 
for Induction 
Treatment 
Maintenance 
Dosage 
Major 
Toxicity 
Ganciclovir 
(Cytovene) 
Intravenous 5 mg/kg, 
Every 12 h, 14–21 d  
5 mg/kg 
 Every24 h 
Hematologic 
Valganciclovir 
(Valcyte) 
Oral 900 mg 
Two times per/d, 21 d 
900 mg 
once/d 
Hematologic 
Foscarnet 
(Foscavir) 
Intravenous 90 mg/kg, 
Every 12 h, 14–21 d 
90–120 mg/kg  
once/d 
Renal 
Cidofovir 
(Vistide) 
Intravenous 5 mg/kg once/wk 
Two time/ day, for 2 wks 
5 mg/kg  
once every 2 wks 
Renal 
Neutropenia 
Fomivirsen Intravitreal 330 µg day 1, day 15 330 µg once monthly Ocular 
d, day; h, hour; wks, weeks 
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2 HCMV AND CANCER 
2.1 Cancer Associated Viruses 
Several DNA viruses are associated with neoplasms. These are referred to as oncoviruses, and 
today include eight human viruses; human papillomaviruses are associated with cervical 
carcinoma, hepatitis B and hepatitis C viruses with hepatocellular carcinoma, Human T-cell 
Leukemia virus-1 with T-cell leukemia, EBV with B-cell lymphoproliferative diseases and 
nasopharyngeal carcinoma, Kaposi’s Sarcoma associated herpesvirus with Kaposi’s Sarcoma 
and primary effusion lymphomas (Carrillo-Infante et al., 2007). Although all these viruses does 
not belong to the same family of viruses, or even do not have a clear pathogenicity yet they all 
can cause cancer.  The most common features of these viruses are the abilities to infect and 
retain in the host cells without completely destroying the host cell, in another term they 
establish persistent and long term infections, and importantly they evade the host immune 
system, reviewed in (Pagano et al., 2004). In the last few decades, observed associations of 
viruses with cancers suggest that about 15-20% of all known cancers may be caused by virus 
infections. This has been an intriguing issue for researchers to study, to understand in depth 
how viruses can cause cancer (Parkin, 2006). Furthermore, apart from the direct effects of these 
viruses on cells, chronic inflammation also plays a very important role in the cancer biology 
and may be caused by pathogens (Colotta et al., 2009). 
2.2 Koch’s Postulates 
Koch's Postulates, is a set of criteria that was established in 1884 by Robert Koch and Friedrich 
Loeffler to identify the causative agent of a particular disease. (reviewed in (Fredericks & 
Relman, 1996)). These criteria applies to almost all microorganisms but some of the criteria 
are not applicable to some viruses, such as oncogenic viruses (Herpesviruses) and parasites. 
These viral infections can take years to induce or promote the malignancy and can be a non-
productive infection, and not able to eliminate it from the host. Due to these reason another set 
of criteria was developed by Frederick and Relman in 1996, especially for a potential infectious 
agent to be considered as aetiological agent in human cancers. The criteria for Koch's Postulates 
for 21st century are as follows: 
 
i. The putative pathogen is present in most cases of the disease.  
ii. Normal tissue should harbour no, or significantly less, putative pathogen.  
iii. Disease resolution should be accompanied by decreased genome of putative 
pathogen. 
iv. Microbial sequences should be present before the disease is established or correlate 
with disease severity.  
v. The nature of the microbial organism detected should be consistent with known 
biological characteristics of that group of organisms.  
vi. Microbe-associated sequences are detected in the diseased tissue and should be 
corroborated at the cellular level.  
vii. Molecular evidence should be reproducible. 
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2.3 Prevalence of HCMV in Cancer 
HCMV nucleic acids and proteins have been found in malignant tumours of the breast (Harkins 
et al., 2010) and its metastatic tumours (Study IV), colon (Harkins et al., 2002), prostate 
(Samanta et al., 2003a), rhabdomyosarcoma (Price et al., 2012), medulloblastoma (Baryawno 
et al., 2011a), nucoepidermoid salivary gland tumours (Melnick et al., 2012), neuroblastoma 
(Wolmer‐Solberg et al., 2013) and glioblastoma (Cobbs et al., 2002c; Rahbar et al., 2012a). 
HCMV proteins were mainly detected in tumour cells, and sometime it may be found in 
inflammatory or endothelial cells in the tumour tissue. Furthermore, no or little HCMV IE 
proteins were found in the healthy tissues surrounding the tumour (Harkins et al., 2002). After 
extensive efforts, infectious HCMV has not been isolated from the primary tumours (my own 
observations in our lab). The prevalence of HCMV in all investigated cancers is close to 100%. 
However, the subject is controversial as some investigators could not find any evidence of 
HCMV in cancers (Forslund et al., 2014; Huang et al., 2014; Yamashita et al., 2014).  Thus, 
the role of HCMV in cancer is still controversial and a matter under debate. Whether HCMV 
infection contributes to cancers pathology, or whether it represents an epiphenomenon of 
cancer warrants further investigation. However, to study various aspects of HCMV on cancer 
cells in vitro, most researchers use cancer cell lines and infect them with HCMV. This may not 
represent the in vivo situation (see below).  
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2.4 Hallmarks of Cancer 
 
 
 
What differentiates malignant cells from normal cells? This question has occupied scientists 
for decades and a simple answer remains elusive. 
Researcher all around the world have been working for many decades to identify differences 
between malignant and normal cells. Cancer is a disease in which the cells abnormally undergo 
uncontrolled proliferation and growth and are able to invade other organs. When these 
abnormal cells disseminate to the other part of the body via the circulation, they may give to 
metastatic disease, which is almost incurable. Till date, knowledge in cancer biology suggest 
that tumorigenesis is a multistep process and to simplify this, Hannahan and Weinberg have 
come up with a description of the hallmarks of cancer. These hallmarks are features shared 
between cancers of different origin; like uncontrolled and sustained cell growth, insensitivity 
to negative growth regulation, resistance to induced cell death, lack of senescence, genomic 
instability, angiogenesis and invasion and metastasis, reviewed by (Hanahan & Weinberg, 
2011). As described in earlier sections, a recent study suggested that HCMV encodes for about 
750 proteins (earlier estimated to be about 180 proteins), indicating that HCMV is a complex 
virus, and the functions of most of these proteins are unknown (Stern-Ginossar et al., 2012). 
HCMV is not considered as an oncovirus, although its proteins have been found in several 
cancer types, and its ‘oncomodulatory’ roles have been studied in depth in cancers. In the 
following sections, I will discuss HCMV´s role in cancer by its ability to mediate the hallmark 
Figure 4. Overview of HCMV genes that interfere with hallmarks of cancer. 
Adapted and Modified from (Hanahan & Weinberg, 2011). 
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of cancers. 
 
2.4.1 Sustained Proliferation 
In normal cells, proliferation involves a coordinated series of events through the cell cycle and 
activation of signalling pathways, which are often directed by growth factors and cytokines etc. 
In cancer cells these signals are disrupted and acquire alternative signals by which cancer cells 
gain capability to proliferate endlessly. Many studies have demonstrated that several signalling 
pathways have alterations such as disruption of autocrine signals of their own growth factors, 
or disruption of paracrine signals from the microenvironment (Bhowmick et al., 2004; Cheng 
et al., 2008). Cancer cells can also increase their expression of growth factor receptors that may 
further sustain chronic proliferation (Bhowmick et al., 2004). For example, in EGF, PDGF, 
PTEN or P13K pathways, one or several genes are mutated, which can lead to consistent 
activation of the pathway, to stimulate growth, survival and proliferation (Jiang & Liu, 2009; 
O'Reilly et al., 2006).  
The Rb family of proteins are inactivated by the HCMV proteins IE72, IE86 (Castillo & 
Kowalik, 2002b), pp71 (Kalejta et al., 2003a) and UL97 (Hume et al., 2008a) and they promote 
the cell cycle to enter the S phase. Furthermore, both HCMV IE72 and IE86 can control the 
cell cycle at several checkpoints through interactions with the tumour suppressor protein p53 
(Castillo & Kowalik, 2002b). Furthermore, HCMV IE proteins activate cell survival pathways 
in both in normal and tumour cells trough induced expression of the transcription factor NF-
kB (Yurochko et al., 1995). HCMV IE proteins also induce the expression of proto-oncogenes, 
cyclins and kinases involved in cell cycle regulation and cellular division (Jault et al., 1995). 
IE72 can also induce proliferation in quiescent cells via trans-activating the E2F-responsive 
promoter by an alleviation of transcriptional repression mediated by protein p107, this plays a 
key role in cell cycle progression (Poma, Kowalik et al. 1996). HCMV infected cell has also 
acquired multiple mechanisms to activate MAPK p38, a kinase that is known to be critical for 
viral infection (Johnson et al., 2000). Furthermore, the HCMV chemokine receptor homologue 
US28 induces production of IL-6, VEGF, and cyclooxygenase-2 (COX-2), and also activates 
STAT-3; these factors play important roles in angiogenesis, tumour cell migration, and 
inflammation and tumour progression (Bongers et al., 2010; Maussang et al., 2006). In a recent 
study from our lab, we demonstrate that HCMV was detected in 92% medulloblastoma. 
Engrafted cells containing HCMV nucleic acids in nude mice exhibited induced HCMV 
protein expression, which was correlated with COX-2 expression in primary tumour cells, cell 
lines and medulloblastoma xenografts. Importantly, the anti-viral drug valgancicovir and the 
COX-2 inhibitor celecoxib prevented HCMV replication in vitro leading to reduced production 
of PGE2 and decreased tumour growth. This study suggest HCMV as a potential target for 
modulloblastoma treatment (Baryawno et al., 2011b). 
 
2.4.2 Evades Apoptosis 
Apoptosis is defined as programmed cell death and is essential for maintenance of tissue 
homeostasis. During infections or in pathologically alerted cells apoptosis plays as an important 
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role and act as an innate defence mechanism. There are two separate pathways that induce 
apoptosis; the extrinsic and the intrinsic pathways; both lead to caspase activation that induces 
cell death. The extrinsic pathway is triggered from the outside of the cell, and is activated by 
death receptors such as the FAS ligand receptor and the TNF-α receptor. The intrinsic pathways 
is regulated by mitochondrial stress, the intrinsic pathways signal may begin form DNA 
damage signals, loss of cell survival factors or other stress signals. The Bcl-2 family of proteins 
play a major role in regulating the intrinsic apoptotic pathway. Furthermore, tumour suppressor 
proteins such as p53 and Rb proteins are also involved  (reviewed in (Danial & Korsmeyer, 
2004)). 
HCMV can regulate or even block apoptosis by several mechanisms. HCMV gene products 
are acting as anti-apoptotic proteins or interfere with apoptotic pathways in one or multiple 
ways. For example, IE86 binds to p53 and blocks activation of apoptosis (Tanaka et al., 1999), 
IE72 and IE86 blocks apoptosis mediated by TNF-α receptor signalling (Zhu et al., 1995). 
Furthermore, UL36/vICA inhibits FAS mediated caspase activation (Skaletskaya et al., 2001) 
and UL37/vMIA inhibits the activity of the pro-apoptotic proteins Bax and Bak (Goldmacher 
et al., 1999). Interestingly, the most abundantly expressed HCMV RNA, the non-coding RNA 
β2.7 inhibits apoptosis in infected U373 glioma cells via stabilizing the mitochondrial 
respiratory chain complex I, by preventing the relocation of an essential sub unit, GRIM-19 
(Reeves et al., 2007). Moreover, HCMV infection induces expression of the Bcl-2 protein in 
infected colon and neuroblastoma cancer cells, which led to resistance to cytotoxic drugs. 
When the cells were treated with antivirals, the resistance was reversed (Cinatl et al., 1998; 
Harkins et al., 2002). 
 
2.4.3 Limitless Replicative Potential 
Normal cells divide under normal circumstances for a certain number of times, and they then 
reach a non-dividing state called senescence. This is a natural process and is controlled by 
several molecular mechanisms. Senescence can be avoided by blocking the tumour suppressor 
proteins pRb and p53, which allow the cells to continuously divide and multiply; this process 
is called immortalization (Wright et al., 1989). Immortalization is a very typical characteristic 
of tumour cells in culture, which they acquire during the transformation process (Hayflick 
1997). The HCMV proteins pp71 and UL97 mediate phosphorylation and inactivation of the 
tumour suppressor Rb family of proteins, thereby modulating the proliferation and survival of 
the cells as typical oncogenic viruses do (Hume et al., 2008b; Kalejta et al., 2003b). Cancer 
cells express telomerase, which is an enzyme that protects the telomeres from shortening during 
each cell division and prevents cellular senescence and sustain cellular division (Deng and 
Chang 2007). High telomerase activity is commonly induced by oncogenic viruses, and this is 
vital for their long lasting survival. Telomerase activity is often induced to multiply infected 
cells as well as for tumour cell growth (Bellon & Nicot, 2008). Our lab has found that the 
HCMV IE72 protein promotes the replicative potential of tumour cells by inducing telomerase 
activity and telomere lengthening via a specific interaction with the hTERT promoter. Strååt et 
al. also found hTERT and IE1 proteins to be co-expressed in GBM tissue samples (Strååt et 
al., 2009). 
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2.4.4 Genomic Instability  
Cancer, and most hallmarks of cancer are considered to be the results of genomic instability, 
and this is one of the very important characteristics of cancer. Genetic instability and mutations 
occur due to deregulated DNA repair pathways. Due to genomic instability, amplifications, 
deletions, and re-arrangements of chromosomal segments, a point mutation or even gain or loss 
of entire chromosomes occur. In DNA repair pathways, p53 is the ‘guardian of genome’, and 
mutations in p53 could lead to loss of control over the DNA repair mechanism. Karyotypic 
instability and associated amplifications and deletions of chromosomal segments occur in most 
cancers due to loss of telomeric DNA, wherefore telomerase activity plays a crucial role in 
maintaining genome integrity (Artandi & DePinho, 2010). 
In infected baby rat kidney cells, the HCMV proteins IE-72 and IE-86 together with adenovirus 
E1A protein induced mutations in the p53 gene as a part of a cellular transformation process. 
Although transformed cells had a mutated p53 gene, HCMV was not found in the transformed 
cells, implying a “hit and run” mechanism for virus induced cellular transformation (Shen et 
al., 1997b). The HCMV UL76 protein can induce micronuclei, misalignment of chromosomes, 
lagging and bridging thereby inducing DNA damage (Siew et al., 2009). Infection with HCMV 
induces DNA breakage in chromosome-1, specifically at positions 1q42, 1q21 and 1q23.3. 
Interestingly, deletion of the 1q42 chromosome segment is associated with glioblastoma (Li et 
al., 1995), which is a tumour that is almost always positive for HCMV. Additionally, certain 
tumour suppressor genes in patients with breast cancer are proposed to be located at 1q21-31 
(Bieche et al., 1995), thus representing a potential target of 1q21 strand break consequences 
that can arise in HCMV infected cells. 
 
2.4.5 Angiogenesis 
Angiogenesis is a process of formation of new blood vessels, which is a very important 
component during solid tumour development. The growth of the tumour mass require blood 
vessels for its maintenance and progression. The initiation of this process is controlled by the 
relative balance of pro-angiogenic (e.g basic fibroblast growth factor bFGF) and anti-
angiogenic factors (e.g thrombospondin-1 (TSP-1)) and the responding vascular endothelial 
cells. Several pro-angiogenic and anti-angiogenic factors are present in different tumour types 
(Hanahan & Folkman, 1996). The pro-angiogenic factors stimulate new blood vessel formation 
with great impact on tumour proliferation and metastasis formation (as reviewed in (Hanahan 
& Weinberg, 2000)). TSP-1 levels were downregulated in tumours with loss of p53 function 
(Dameron et al., 1994). In cancers, VEGF expression could also be induced by the indirect 
activation of oncogenes or deregulated tumour suppressor genes (Maxwell et al., 1999; Rak et 
al., 1995). 
HCMV has modulated multiple ways to promote angiogenesis and it acts as a pro-angiogenic 
factor. Cell-free supernatants obtained of HCMV-infected cells contain higher levels of pro-
angiogenic molecules and promote angiogenesis in vitro (Dumortier et al., 2008). In infected 
glioma cells, HCMV IE is also found to induce angiogenesis either via suppression of TSP-1 
expression or via induced production of IL-8 (Murayama et al., 1997) in glioma cells (Brat et 
al., 2005). In infected glioblastoma cells US28 was shown to be involved in the viral induced 
angiogenic phenotype via induced production of VEGF (Maussang et al., 2006) and also by 
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promoting growth and invasion via phosphorylation of STAT3 and eNOS (Soroceanu et al., 
2011). It has been proposed that HCMV gB proteins bind to PDGFR-alpha and this leads to 
intracellular phosphorylation of the receptor which leads to enhanced migration and 
angiogenesis in GBM cells (Soroceanu et al., 2008), Furthermore, HCMV-mediated activation 
of COX-2 may also promote angiogenesis in GBM cells; this is also mediated by US28. COX-
2 further induces the expression of VEGF, bFGF, PDGF, iNOS, and TGF-α in tumour cells, 
which may result in further angiogenesis and endothelial cell migration (Tsujii et al., 1998). 
 
2.4.6 Immune Evasion  
Cells of the immune system are constantly patrolling tissues to identify pathologically alerted 
cells. Most cancer cells have developed immune evasion strategies to escape recognition by 
the immune system by various molecular and cellular mechanisms. Briefly, the host immune 
system is not effectively recognizing the cancer cells as they are disabled in presenting the 
antigens on their surface, they have reduced HLA class I molecules on their surface. The ability 
to avoid immune recognition is essential for the existence of cancer (Drake et al., 2006). 
Furthermore, tumour-related elements such as secretion of immunosuppressive cytokines, and 
deficient expression of immunomodulatory molecules and resistance to apoptosis orchestrate 
many important roles in controlling the immune response to cancer, reviewed in (Seliger, 
2005).  In the tumour microenvironment, PGE2 and the immunosuppressive cytokines TGF-β 
and IL-10 orchestrate the anti-tumour immune response (Gomez & Kruse, 2006). In cancer 
patients who have tumours heavily infiltrated with NK cells and Cytotoxic T Lymphocytes 
(CTL) have a better prognosis in terms of disease free overall survival time at all stages of 
disease than patients with low levels those cells in their tumours (reviewed in (Pages et al., 
2010)). 
Under normal circumstances, HCMV maintains a balance with its host’s immune system, it 
stimulates the immune response and induces the inflammation, and at the same time it has 
developed numerous immune evasion strategies. It has established multiple sophisticated 
strategies to affect immunological, molecular and cellular pathways to avoid detection by all 
arms of the immune system. This will allow for a persistent infection and virus spread without 
harming the infected cancer cells/normal cells.  
HCMV infection interferes with antigen presentation 
HCMV encoded gene products interfere with antigen presentation, suppression of antigen 
presentation and prevent the T- cell response in infected cells. HCMV US2 and US3 proteins 
downregulate the surface expression of MHC class-II, which avoids the recognition by the 
CD4+ T cells (Miller et al., 2001). Furthermore, the HCMV protein US6 inhibits TAP-
mediated peptide translocation in the endoplasmic reticulum (ER), US3 causes retention of 
MHC-I molecules into the ER, US11 causes displacement of the MHC-I heavy chain into the 
cytoplasm, and US2 helps to export the MHC-I heavy chain from the ER. Thus, HCMV 
encoded gene products interfere with antigen presentation, suppress antigen presentation and 
prevent the T cell response in infected cells (Soderberg-Naucler, 2006). 
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HCMV infection interferes with the NK cell response 
 NK cells provide a very important line of defence important for killing of infected cells and 
tumour cells. HCMV has evolved unique strategies to evade its own virally mediated 
downregulation of MHC class I antigen to overcome NK cell recognition, reviewed in 
(Soderberg-Naucler, 2006). Here, I mention some of the mechanisms: NK cell inhibitory (LIR-
1) and activating (NKG2D) receptors are expressed on NK cells and regulate NK cell functions 
(Arase et al., 2002). HCMV UL18 is an MHC class I homologue protein, which mimics MHC 
class-I molecule and inhibits the NK cell response by triggering the inhibitory receptor LIR-1 
(Wilkinson et al., 2008). This also prevents activation of NK cells via the “missing self-
hypothesis”. 
In summary, HCMV’s different roles in in vitro cancer studies are eminent, and in animal 
studies anti-viral treatment suppressed tumour growth (Baryawno et al., 2011a). In patients, 
the time to metastasis development and the survival was shorter in breast and colon cancer 
patients with high grade HCMV infection (Taher et al., 2014). Patients diagnosed with high 
grade of HCMV infection in GBM tumours had shorter survival (Rahbar et al., 2012c), and 
importantly treatment with valganciclovir in GBM patients indicate increased survival rates 
(Söderberg-Nauclér  et al., 2013). Thus, as a pathogen HCMV also follows the 21st century 
Koch’s postulate criteria, especially its association in cancers. Furthermore, as extensively 
described, HCMV directs the hallmarks of cancer via its oncomodulatory mechanisms. 
Although, HCMV studies so far failed to transform normal cells into cancer cells. Treatment 
with antivirals to CMV as add on to standard therapy give hope for improved survival of GBM 
patients. Thus, I believe HCMVs role in cancer needs to be further evaluated to improve the 
patient outcome. 
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3 MicroRNAS  
3.1 Background 
In 1958, the central dogma of molecular biology describing ribonucleic acid (RNA) as a 
mediator between deoxyribonucleic acids (DNA) and proteins was proposed, while proteins 
play the significant role in all natural molecular pathways (Crick, 1970). In the last few decades, 
the knowledge of RNA biology has expanded significantly. This includes the discovery of 
different types of RNA molecules such as transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), 
small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), small interfering RNAs 
(siRNAs), microRNAs (miRNAs) and long non-coding RNAs (lncRNA). Furthermore,  their 
respective functions in biology have been elucidated by extensive research (Eddy, 2001; Fire 
et al., 1998; Kruger et al., 1982). 
In the human genome, about 90% of the sequence is transcriptionally active, though only less 
than 2% of the genome encodes protein-coding genes (Stein, 2004; Taft et al., 2010). These 
observations suggest that non-coding RNA plays important roles in cellular development, 
translation and mRNA biogenesis (Brosnan & Voinnet, 2009). In general, based on their length, 
non-coding RNA can be classified into two broad categories, i.e. long non-coding RNA (>200 
nucleotides – 100 kb) and small non-coding RNA (<200 nucleotides). To date, more than 1500 
long non-coding RNA genes had been annotated (Gencode 25) and more than 250 of them had 
been characterized functionally (http://www.lncrnadb.org/). Viruses, including several 
members of the herpesviruses, are also known to encode both lncRNAs and miRNAs. For 
example, human cytomegalovirus (HCMV) encodes four lncRNAs (RNA1.2, RNA2.7, 
RNA4.9 and RNA5.0) and 26 miRNAs. In this thesis, I will describe the basics of miRNAs 
biology with in-depth focus on HCMV encoded miRNAs.  
3.2 Discovery of miRNA 
In 1993, for the first time a small RNA molecule, lin-4, was discovered in Caenorhabditis 
elegans (C. elegans). Lin-4 represses lin-14 protein expression, by which it regulates the timing 
of larval development (Lee et al., 1993; Wightman et al., 1993). It was thought to be specific 
for C. elegans, and almost seven years later another study found a similar function with another 
small RNA named let-7 (Reinhart et al., 2000). As let-7 is conserved among other species, 
most researchers were intrigued and investigated if these tiny RNA molecules were functional 
(Pasquinelli et al., 2000). In 2001, using cloning methods, about 100 small RNAs with 18-22 
nucleotides were identified in worms, flies and human cells by three independent laboratories 
and the term “miRNA” was coined (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee & 
Ambros, 2001).  
After these studies, miRNAs were identified in several different species, and the development 
of the knowledge of the miRNA has expanded significantly. To date, 30,424 miRNAs have 
been identified from 206 species, and 2,578 human encoded miRNAs have been annotated in 
the miRNA database (www.mirbase.org version 20). It has been estimated that 60% of protein 
expression occurring in cells is controlled by miRNAs (Friedman et al., 2009). 
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3.3 Genomic location and biogenesis 
The biogenesis of miRNAs begins within the nucleus by transcription. The miRNA-encoding 
transcripts are located in various regions of the genome such as in introns of protein-coding 
genes or within the intergenic regions, and less frequently within exons or as antisense to 
mRNA transcripts. Furthermore, many miRNA encoding transcripts exist in clusters (Lagos-
Quintana et al., 2003; Rodriguez et al., 2004). 
Intergenic miRNAs have their own transcriptional regulatory region/promoter and these are 
independent units of transcription. Those miRNAs that are located within introns of genes are 
usually co-transcribed with their host gene transcription and their expression levels are mostly 
similar to their host mRNA transcripts (Aravin et al., 2003; Lai et al., 2003; Lim et al., 2003). 
The biogenesis of the miRNAs has been described using two major pathways: 
  
Figure 5. Overview of the miRNA biogenesis. Adapted and modified from (van 
Rooij & Kauppinen, 2014) 
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Canonical biogenesis pathway 
Primary-miRNAs are produced as RNA transcripts by RNA Pol II or Pol III, and partly fold 
into the stem-loop structure (Borchert et al., 2006; Han et al., 2006; Lee et al., 2004). Each 
stem-loop structure is cleaved at stem and become a short 60-100 bases stem-loop structure 
called precursor miRNA (pre-miRNA). The cleavage is mediated by two proteins: RNase III 
endonuclease Drosha and a double-stranded RNA-binding protein DiGeorge syndrome critical 
region gene 8 (DGCR8) (collectively called microprocessor complex) (Denli et al., 2004; 
Gregory et al., 2004; Han et al., 2004; Lee et al., 2003; Lee et al., 2002). These pre-miRNAs 
are translocated from the nucleus to the cytoplasm of the cell by Ran-GTP and Exportin-5 
protein complex (Bohnsack et al., 2004; Okada et al., 2009; Yi et al., 2003; Zeng & Cullen, 
2004). The loop structures of the pre-miRNA are then cleaved by the Dicer and TARBP2 
complex and become a duplex miRNA (only stem) consisting of two strands. The passenger 
strand is mostly degraded and the other leading strand is incorporated into the Argonaute-
containing protein complex (RNA-induced silencing complex, RISC) and targets the mRNA 
transcripts (Chendrimada et al., 2005).  
Non-canonical biogenesis pathway 
Some miRNAs can be processed independently of Drosha or Dicer processing.  Those miRNAs 
that bypass Drosha processing are termed mirtron and there are hundreds already identified 
(e.g. miR-877 and miR-1224). The pre-miRNA is generated directly from splicing, as it is 
directly adjacent to the splice sites (Babiarz et al., 2008; Berezikov et al., 2007; Okamura et 
al., 2007; Ruby et al., 2007). Furthermore, apart from mitrons, there are several exceptional 
miRNAs which are also processed via non-canonical pathways (e.g. has-miR451).  
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3.4 Mechanism of Function 
MiRNA expression pattern is temporal and tissue-specific, suggesting their important roles in 
almost all biological processes (Ambros, 2004; Bartel, 2004). To date, it has been well 
established that miRNAs suppress gene expression at post-transcriptional level and most 
reports suggest that they downregulate protein expression. One miRNA can target one or 
multiple mRNA transcripts, and one single mRNA can also be targeted by multiple miRNAs, 
which make them act in very complex regulatory networks (Bartel, 2004; Tang et al., 2012; 
Zhou et al., 2013; Zisoulis et al., 2012). Furthermore, the complexity of these networks 
increases when the host or pathogen miRNA targets each other’s mRNAs and drives disease 
pathogenesis through their effects on biological processes. However, there are also 
accumulating evidence suggesting that miRNA can also induce protein expression (Mortensen 
et al., 2011; Truesdell et al., 2012; Vasudevan et al., 2007). Interestingly, in HCV infection the 
host liver-specific miR-122 binds to 5’UTR of HCV RNA stimulating its translation (Henke et 
al., 2008) and also protecting it from host exonuclease Xrn1 degradation (Li et al., 2013). 
Importantly, anti-miR treatment against miR-122 alleviate from HCV infection (Janssen et al., 
2013). 
The functional mechanisms of miRNAs have been described in two major steps: i) Target 
recognition, and ii) Translational inhibition or mRNA degradation. 
Target Recognition 
Several mature miRNA characteristics play a crucial role in targeting mRNAs. Among these, 
the seed region of the miRNA is a very important feature. The miRNA seed is the nucleotides 
located at 2 – 8 position on the 5’ end of the mature miRNA. This seed sequence binds to its 
complementary sequence on the mRNA and regulates gene expression (Lewis et al., 2003). 
There are several sub-types of seed regions that have been experimentally found and validated, 
such as 8 mer, 7 mer and 6 mer (Bartel, 2009). Apart from the seed region, additional 
complementary sequences throughout the miRNA gives higher. Several other determinants can 
also contribute to the efficacy of miRNA target recognition. These include AU-rich nucleotide 
compositions, the proximity of several miRNA targets, that the target site is closer to the stop 
codon in the 3’UTR region (at least 15 nt), or its position away from the centre of the long 
UTRs (Grimson et al., 2007). There are several miRNA target prediction tools/ databases 
available online such as PicTar (http://pictar.mdc-berlin.de/) (Krek et al., 2005), TargetScan 
(www.targetscan.org/vert_71/) (Lewis et al., 2005) and Microcosm (www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/#) (Griffiths-Jones et al., 2008). These tools/databases, 
however, are not useful to predict viral miRNA targets. In fact, to our knowledge, reptar 
(http://reptar.ekmd.huji.ac.il/) (Elefant et al., 2010) and RNA hybrid (Krüger & Rehmsmeier, 
2006) are the only tools that can be used for target predictions of viral miRNAs. As databases 
of published human and viral miRNA targets/ miRNAs, miRTarBase, and VIRmiRNA tools, 
respectively, can be very useful. 
Translational Repression 
In general, the imperfect base pairing of miRNA and mRNA leads to translation repression. 
The mechanisms by which mRNA translation is inhibited is still not fully elucidated. However, 
few reports suggest that miRNAs interfere with translational initiation and/or elongation 
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(Petersen et al., 2006; Pillai, 2005). Disruption of the translational initiation complex formation 
can occur via dissociation of the poly-A binding proteins (PABP) from the poly-A region of 
the mRNA by the miRNA-RISC complex, that recruits CCR-NOT to this region (Zekri et al., 
2013). On the other hand, it has been suggested that during the translational elongation process, 
the miRNA-RISC complex promotes ribosomes drop-off (Petersen et al., 2006). The 
translational repression is suspected when the mRNA levels are almost stable, but the protein 
levels are decreased, however, this might not apply for stable proteins or it depends on the 
miRNA turnaround time. 
mRNA Degradation 
In plants, miRNA-mediated target degradation of mRNAs is a common mechanism which 
requires a perfect base-pairing of the entire miRNA sequence with the mRNA and it is mediated 
by the Argonaut proteins (Yekta et al., 2004). In animal cells, miRNA-mediated degradation 
directs the target mRNAs to the cellular mRNA decay pathway. The miRNA-RISC complex 
recruits the CCR4-NOT deadenylation complex to the site of the poly-A region and removes 
the poly-A tail of the mRNA (Behm-Ansmant et al., 2006). The loss of the poly-A tail also 
results in mRNA degradation by the major cytoplasmic exonuclease Xrn1 (Ambros, 2004; 
Meister & Tuschl, 2004). The mRNA degradation is suspected when both mRNA and protein 
levels decrease and it can occur in the case of stable proteins. 
3.5 Herpesvirus miRNAs 
Viruses can encode miRNAs from their genome, despite not having their own miRNA 
biogenesis machinery. In 2004, for the first time, EBV was shown to encode miRNAs 
(organised in two clusters in the genome). These were identified in latently EBV-infected 
Burkitt’s lymphoma cell line by small RNA cloning and validated by northern blot (Pfeffer et 
al., 2004). Later, several studies also found miRNAs in other viruses, including members of 
the herpesvirus family, retroviruses, adenoviruses and polyomaviruses. To date, 502 mature 
viral-encoded miRNAs have been identified in 29 different viruses, among which 277 (55%) 
miRNAs are encoded by 13 different herpesviruses (April-2017, www.mirbase.org). In 
contrast to the human miRNA annotations, viral miRNAs are annotated according to their 
nearby gene names. miRNA loci are arranged in clusters in the genome of most of the 
herpesviruses, whereas most miRNAs in HCMV are distributed across the genome. 
Accumulating evidence suggest that viral miRNAs and host miRNAs play a vital role in virus 
– host interactions and biology.  
DNA viruses that replicate in the nucleus of the infected cells likely utilise the host miRNA 
biogenesis machinery to process the viral miRNAs. Several studies have also investigated the 
presence of miRNAs in RNA viruses, and they reported the presence of miRNA in bovine 
leukaemia virus (BLV) (Kincaid et al., 2012)  and HIV (Omoto & Fujii, 2006). These findings 
remain under debate and need more validation and functional studies. However, importantly, 
how miRNA biogenesis takes place for RNA viruses remains a big question to resolve. 
3.6 HCMV Encoded miRNAS 
In 2004, Pfeffer et al cloned nine miRNAs from HCMV infected human foreskin fibroblasts 
(Pfeffer et al., 2004). The following year, more evidence was accumulated by two independent 
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laboratories that used in silico methods. They predicted several HCMV miRNAs and their 
existence was further confirmed by northern blots and cDNA cloning (Dunn et al., 2005; Grey 
et al., 2005). To date, HCMV encoded 26 miRNAs are identified and sequences are available 
in miRBase database (www.mirbase.org), HCMV encoded miRNAs can target 3’UTR (Kim 
et al., 2015) and 5’UTR of both viral and host transcripts (Grey et al., 2010b). In a study using 
a rat model, cytomegalovirus miRNAs expression is tissue specific and varies among the 
organs (Meyer et al., 2011). A recent study found that a 15 kb segment in the UL/b0 region can 
act as ‘miRNA decay element’ (miRDE), which regulates the turn-over of particular cellular 
miRNAs (Lee et al., 2013). To our knowledge, this is a novel mechanism of action found 
among the herpesviruses.  
3.6.1 HCMV miRNAs Affect Several Host Cell Functions 
Similar to the cellular miRNAs, the viral miRNAs encoded by HCMV regulate several 
biological processes such as cell cycle or apoptosis. For example, an in vitro screening study 
using co-immunoprecipitation of myc-tagged Ago2 / biotin conjugated synthetic miRNA 
mimic found that the HCMV miRNA miR-US25-1 targets several cell cycle controlling or 
tumour proliferation genes (such as cyclin E2, BRCC3, EID1, MAPRE2, and CD147) in HEK-
293 cells (Grey et al., 2010b). Most miRNAs are known to target the 3’UTRs, however, Grey 
et al was the first to show in herpesviruses that 5’UTRs is the major target site for the miR-US-
25-1. By regulating cyclin E2 levels, miR-US25-1 promotes the cell cycle arrest in G1 phase, 
which provides favourable conditions for HCMV infection (Grey et al., 2010b). In another 
study miR-US25-1 expression, in the presence of the oxidised low-density lipoprotein, but not 
alone, induced apoptosis in endothelial cells. Furthermore, miR-US25-1 expression was 
significantly higher in the blood of HCMV serology positive atherosclerosis patients and 
healthy donors  (Fan et al., 2014). On the other hand, miR-UL148D targets the human 
immediate early gene X-1 and exerts anti-apoptotic effects on cells (Wang et al., 2013). Using 
silico methods, miR-UL148D and miR-UL70-3p were found to target several pro-apoptotic 
genes, but these observations need validation in in vitro experiments (Babu et al., 2014).  The 
over-expression of miR-US25-2-3p results in downregulation of Eukaryotic translation 
initiation factor 4A1 (eIF4A1) and this leads to inhibition of translation, suppression of host 
cell proliferation and also inhibits virus replication (Jiang et al., 2015; Qi et al., 2013). Another 
study found that miR-UL112-1 targets the BclAF1, which is an anti-viral protein that is known 
to be downregulated by virus delivered pp71 and UL35 proteins and essential for viral gene 
expression and replication (Lee et al., 2012). Furthermore, miR-US25-1 also targets several 
cellular genes that inhibit viral replication, such as YWHAE, UBB, NPM1, and HSP90AA1 
(Jiang et al., 2015). 
On the other hand, the HCMV infection is also studied by manipulating the miRNA biogenesis 
machinery. Two animal studies have been conducted using infection with mouse 
cytomegalovirus (MCMV) in Dicer mutant mice. These mice have increased susceptibility to 
infection and this is correlated with the deregulation of type-I IFNs (Ostermann et al., 2012). 
Furthermore, when Dicer-deficient neonate mice were infected with MCMV, the virus was 
highly disseminated to the brain, and the infected mice exhibited increased lethality 
(Ostermann et al., 2015). 
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3.6.2 HCMV miRNA -mediated Immune Evasion 
Immune evasion is an important part of virus pathogenicity and not surprisingly, HCMV 
miRNAs target several proteins involved in the anti-viral immune response from the host. An 
important example is the HCMV miR-UL112 which can interfere with the cell-mediated 
immune response by downregulating expression of several different proteins. Bioinformatical 
predictions revealed that HCMV miR-UL112 is located antisense to the UL144 transcript 
(DNA glycosylase), and it can target the gene expression of UL144 (Stern-Ginossar et al., 
2009). HCMV- miR-UL112 targets and downregulates HCMV IE72 and inhibits viral 
replication (Grey et al., 2007). IE72 is one of the major IE proteins that directs the infected 
cells toward the lytic phase of infection by acting as a trans-activator for the production of early 
and late proteins, and it is also essential for replication of the virus. It was proposed that 
targeting of IE72 with miR-UL112 may favour the establishment of a latent infection, thus 
these experiments were repeated in latency models using monocytes and THP-1 cells. Using a 
mutant virus that lacks the miR-UL112 binding site of the IE72 gene, it was confirmed that 
downregulation of IE72 also occurs in these cells. Furthermore, infected cells were not 
recognised by IE specific cytotoxic T-cells, suggesting that miR-UL112 plays a major role in 
latent infection and mediate immune evasion mechanisms (Lau et al., 2016b). Another study 
showed that HCMV- miR-UL112 inhibits secretion of Interferon type-I and attenuates T cell 
activity (Huang et al., 2015). The hcmv-miR-UL112-3p also targets toll-like receptor 2 
(TLR2), which inhibits NFκB signalling and leads to avoidance of the innate immune 
response (Landais et al., 2015). HCMV-miR-UL112 can also directly or together with host 
miRNAs (Stern-Ginossar et al., 2009). HCMV- miR-UL112 also targets and downregulates 
HCMV IE72 and inhibits viral replication (Grey et al., 2007). Also target the stress ligand 
MICB (3’UTRs). Downregulation of MICB expression will prevent the infected cells to be 
recognised by the NK cells. In addition, hcmv-miR-US25-2-3p targets tissue inhibitors of 
metalloproteinase-3 (TIMP3), which leads to increased shedding of MICA proteins also 
contributing to a decreased recognition by NK cells (Esteso et al., 2014). Finally, another 
strategy for escape of NK cell responses involves the induction of the expression of the short 
form of the RNA editing enzyme ADAR1 (ADAR1-p110). This enzyme is responsible for the 
editing of the cellular miR-376a, which then will target HLA-E gene expression (Nachmani et 
al., 2014). One of the mechanisms of evasion from CD8+ T cell response during HCMV 
infection is through the HCMV miRUS4-1 that has been shown to target ERAP1 and limit the 
viral peptide loading on MHC-I (Kim et al., 2011). However, a later study using next 
generation sequencing suggested that the miR-US4-1 sequence was inaccurate, which 
questions the validity of the study (Stark et al., 2012).  
Viral miRNAs can also inhibit secretion of pro-inflammatory cytokines, which would result in 
reduced recruitment of immune cells at the sites of infection. HCMV infection induces the 
production of the pro-inflammatory cytokine IL-32 and hcmv-miR-UL112 downregulates the 
production of IL-32 (Huang et al., 2013b), which suggest that this miRNA prevents the 
secretion of IL-32 to evade the immune response.  
Several HCMV encoded miRNAs (UL112-1, US5-1, and US5-2) were also identified (Ago2 
immunoprecipitation) to target secretory pathway genes such as VAMP3 (vesicle-associated 
membrane protein 3), RAB5C (RAS-related protein 5C), RAB11A (RAS-related protein 11A), 
SNAP23 (synaptosomal-associated protein, 23 kDa), and CDC42 (cell division control protein 
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42). Infection of cells with viruses lacking these miRNAs resulted in an increase in defective 
particle production and failed to form the virus assembly compartment and increase the 
secretion of TNF-α and IL-6 (Hook et al., 2014). A recent study of in vitro infected primary 
myeloid cells also demonstrated that miR-UL148D prevented upregulation of ACVR1B 
expression, which led to the limited release of pro-inflammatory cytokines from infected 
primary myeloid cells. This protein is a cellular receptor of the activin signalling axis known 
to promote differentiation of monocytes into dendritic cells (Lau et al., 2016a). hcmv-miR-
UL148D also regulates production and release of the chemokine RANTES (Kim et al., 2012). 
hcmv-miR-UL148D is accumulated in CD34+ infected cells and targets the IER5 gene which 
results in upregulation of CDC25B, which plays a major role in inhibition of IE-72 gene by 
activating the CDK-1 (Pan et al., 2016). Thus, these results suggest that miR-UL148D plays a 
major role in modulating the immune response or controlling re-activation of latent infection. 
3.6.3 Expression of HCMV miRNAs during Latency 
Host miRNAs regulated by the HCMV infection and HCMV encoded miRNAs are known to 
play key roles in the establishment and maintenance of latency. As of today, it has been 
established that HCMV remains latent in CD34+ myeloid lineage cells. To study latency in 
vitro, several models have been established, such as infection of the monocytic leukaemia cell 
line THP-1, infection of CD34+ cells from donors or studies of HCMV positive CD34+ cells 
obtained from HCMV IgG positive individuals.  
There are three in vitro infection studies published so far, in which the viral miRNAs are 
investigated during the latency phase of infection using THP-1 infected cells. One study studied 
the permissive (lytic), semi-permissive and non-permissive (latent) infection, and found a 
differential expression of viral miRNAs during the latent and lytic infection phases (Shen et 
al., 2014). Next generation sequencing of small RNAs in HCMV infected THP-1 cells 
confirmed that they were differently expressed; the eight HCMV encoded miRNAs (highest to 
lowest in order: US25-1-5p, US25-2-5p, UL112-3p, US5-2-3p, US4-5p, US5-1-3p, US25-2-
3p, UL36-5p), and these also altered the expression of the host miRNAs (39 were upregulated, 
and 14 were downregulated). These viral miRNAs target various biological pathways such as 
melanogenesis, cancer, endocytosis and WNT signalling (Fu et al., 2014).  Later, another study 
found eight out of twenty HCMV miRNAs (US22-5p, UL112-3p, UL36-5p, US29-3p, UL36-
3p, US22A-5p, UL112-5p and US5-1-3p) in THP-1 cell line at 10 day post infection. Among 
these, six miRNAs (underlined) were new and were not detected by Fu et al.(Meshesha et al., 
2016). Finally, in a third study, 16 HCMV encoded miRNAs were examined in THP-1 infected 
cells and reported that only 13 were detected, with two new miRNAs which are not found in 
both previous studies (Fu et al and Meshesha et al). However, they only showed data from four 
representative miRNAs (UL112, UL22A-5p, UL70-3p and US33-3p) (Shen et al., 2014). In 
summary, a total of 16 HCMV miRNAs were shown to be expressed in the HCMV infected 
THP-1 cells, though the discrepancy among the studies needs more in-depth investigation, 
before studying functional relevance of these miRNAs in latency. 
Another approach used monocytes obtained from three healthy donors and eight HCMV 
encoded miRNAs (US22-5p, UL112-3p, UL36-5p, US29-3p, UL36-3p, US22A-5p, UL112-
5p and US5-1-3p) were found. Interestingly, these miRNAs are the same as the miRNAs 
present in the in vitro infected THP-1 cells. Furthermore, reactivation of latent HCMV in 
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monocytes with dexamethasone resulted in differentiation into macrophages, and restoration 
of expression of 17 out of 19 HCMV encoded miRNAs, including those which were absent in 
monocytes. These observations suggest that viral miRNAs may play a key role in maintenance 
and reactivation of latent HCMV infection (Meshesha et al., 2016). 
3.6.4 Roles of Host miRNAs in Latent HCMV Infection 
HCMV infection alters expression of host miRNAs (Lee et al., 2013; Wang et al., 2008), and 
accumulating evidence suggest that host miRNAs play crucial roles in establishing and 
maintaining latency. A recent in vitro study of HCMV infected CD34+ progenitor cells found 
that HCMV down-regulates the cellular miRNA miR-92a, which leads to upregulation of the 
cellular transcription factor GATA-2 (Poole et al., 2011) and increased expression of cellular 
IL-10 (Mason et al., 2012). GATA-2 play an important role in myeloid cell differentiation, 
suggesting that the GATA-2 might be a key regulator for the establishment of the latency.  
Furthermore, the latency associated IL10 (LAcmvIL-10) is expressed during the latent phase 
of infection and has been suggested to modulate the production of CCL8 via suppression of the 
expression of host miR-92a (Poole et al., 2014). 
Another interesting study described how the miR-200 family of miRNAs can target the 3’UTR 
of UL122 transcript (IE2) in HCMV infected CD34+ hematopoietic progenitor cells and 
reducing the production of the IE2 protein. Infection with a virus containing a mutated miRNA-
binding site in the 3’UTR of IE2 results in increased expression of IE2 and higher production 
of extracellular virus. Moreover, members of the miR-200 family are highly expressed in the 
CD34+ hematopoietic progenitor cells and monocytes but not in macrophages, suggesting that 
these miRNAs may play a crucial role in suppressing lytic infection and promoting the 
maintenance of latent infection (O'Connor et al., 2014). 
On the other hand, UL138 protein is known to be required for the establishment and 
maintenance of latent HCMV infection (Goodrum et al., 2007a; Petrucelli et al., 2009). 
Overexpression of the miR-UL36 can downregulate UL138 during the first 24h in the lytic cell 
models, however, this study needs confirmation in the latent infection model (Huang et al., 
2013a).  
Apart from the latency, HCMV can also alter host miRNA expression involved in other cellular 
processes. For example, two host miRNAs are upregulated in the HCMV infected endothelial 
cells, in which miR-217 targets SIRT1 and FOXO3A for promoting angiogenesis (Zhang et 
al., 2013a) and miR-199a-5p targets SIRT1 and eNOS that enhances cell migration and tube 
formation (Zhang et al., 2013b). HCMV proteins IE1, pp71, and UL26, downregulates host 
miR-21, which leads to decrease in expression of Cdc25a a cell cycle regulator gene, which 
facilitates the HCMV replication. Suggesting miR-21 inhibits the replication of the virus in 
neural cells (Fu et al., 2015), and miR-21 is known to be one of highly expressed miRNA in 
almost all solid tumours.  
3.6.5 HCMV miRNAs as Biomarkers of Disease 
In human subjects, hcmv-miR-UL112 was found highly expressed in plasma samples from 
hypertension patients and associated with increased risk of high blood pressure. Furthermore, 
in vitro experiments suggested that hcmv-miR-UL112 can target IRF-1, and proposed that this 
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could upregulate angiotensin II type 2 receptor expression, which exerts anti-proliferative and 
pro-apoptotic actions and regulates blood pressure (Li et al., 2011). However, it could be a 
consequence rather that cause because cytomegalovirus is known to be associated with 
cardiovascular diseases (Marques & Morris, 2012). Also, 91% of the patients with solid organ 
transplantation had at least one HCMV miRNA, in which miR-UL112-3p and miR-UL22A-
5p were detected in over 70% of the patients (Lisboa et al., 2015).  
Another study assessed the expression of HCMV miRNAs in blood of solid organ transplant 
recipients and found that several HCMV miRNAs are expressed. In fact, about 92% of patients 
had at least one HCMV miRNA expressed. More specifically, hcmv-miR-UL112-3p and 
hcmv-miR-UL22A-5p were detected in over 70% of the patient’s blood. The levels of miR-
UL22A-5p were significant at baseline independently predicted the recurrence of HCMV 
viremia upon cessation of treatment (Lisboa et al., 2015). In addition, our group detected miR-
UL112 in plasma samples from patients with several HCMV-associated diseases (Study-II), 
and three other HCMV encoded miRNAs (miR-UL22A-3p, miR-UL36-3p and miR-US25-2-
3p) (Study-V) in breast cancer tissues.  
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4 RESULTS AND DISCUSSION 
4.1 STUDY-I 
Isolation and characterization of novel genetic variant of HCMV highly associated with 
tumours of different origin 
Background 
HCMV encoded proteins or viral nucleic acids have been found in several cancer types, but 
not in surrounding healthy tissues, which indicates a possible role of HCMV in those tumours 
rather than representing a mere epiphenomenon. However, an association of HCMV with 
cancers has remained a controversial topic since several studies could not find evidence of 
HCMV in tumours. Thus HCMV´s association with cancers has continued to be a controversial 
topic. While investigating the wild type HCMV genome in colon cancer samples using nested 
PCR primers against the MIE gene (from exon-2 to exon-3), we virtually, by accident, found 
that the size of the PCR product in an agarose gel was smaller than expected. Surprisingly, the 
PCR product aligned to the HCMV genome with a frame deletion, the intron 2 of the immediate 
early gene, suggesting a new variant virus/strain. Next, we screened different cancer tissues 
and controls for the presence of the same genetic variant, and investigated the prevalence of 
this unique HCMV variant in cancer specimens, in clinical HCMV isolates and in healthy 
carriers. We named this variant virus CMVIE△int2. Furthermore, we isolated this virus from 
one clinical sample, and we were able to plaque purify it from the wild type virus that was also 
present in the same clinical isolate. 
Results and discussion 
In this study, frozen tissues of glioblastoma, neuroblastoma, medulloblastoma, colon and breast 
cancer samples were used to isolate the DNA and RNA with Trizol Reagent (life technologies). 
Formalin-fixed paraffin-embedded or fresh tumour samples are used for immunohistochemistry 
(IHC) staining for HCMV proteins. We also examined 50 primary glioblastoma cells for HCMV 
antigens and nucleic acids by flow cytometry, Western blot, fluorescence in situ hybridization 
or nested-PCR and/or Taqman PCR. 
The presence of nucleic acids of the HCMV wild type and CMVIE△int2 variant were examined 
by nested-PCR and/or Taqman PCR in 322 tumor samples, 24 plasma samples of myocardial 
infarction patients, 11 viremic patients (9 mononucleosis and 2 transplant patients), 140 
macrophage preparations from healthy blood donors, and clinical HCMV isolates (n=110). The 
PCR products were validated by Sanger sequencing using appropriate forward and reverse 
primers to the HCMV specific sequences. 
Detection of a HCMV MIE gene variant lacking intron 2 was found in high prevalence in 
tumour tissues 
A nested PCR assay using primer pairs spanning from the end of exons 2 to the beginning of 
exon 3 of the MIE gene were applied to investigate the HCMV IE DNA sequence. Furthermore, 
we developed a highly specific TaqMan PCR assay that uses DNA-specific probes to detect 
the CMVIE△int2 variant. We determined that 154 of 322 (48%) examined cancer specimens 
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were positive for the CMVIE△int2 variant; 95 of 322 (47%) cancer specimens were positive 
for HCMV DNA wild-type virus; 68 of 322 (20%) patients were positive for both the wildtype 
and the CMVIE△int2 variant. Furthermore, 27 of 50 (54%) primary glioma cultures were 
positive for HCMV wildtype DNA, and 41 (82%) of 50 had the CMVIE△int2 variant. The 
CMVIE△int2 variant was also detected in 20 (14%) of 140 blood cell samples from healthy 
donors, in the plasma of 1 (9%) of 11 viremic patients, and in 2 (8%) of 24 patients with 
myocardial infarction. All the examined 110 clinical isolates were positive for HCMV wild 
type, three (3%) of the 110 clinical isolates were also positive for the CMVIE△int2 variant. In 
a few samples that were positive for the CMVIE△int2 variant, we found the presence of the 
promoter, as well as intron 1 and intron 3 regions. These observations suggest that the 
CMVIE△int2 genotype is a variant virus rather than a cDNA made from an mRNA template 
with the aid of a reverse transcriptase. 
To our knowledge, this is the first report that found the intron-2 deleted strain of HCMV. These 
findings imply that a novel genetic HCMV variant, lacking intron-2 of the MIE region is 
associated with cancers of different origin. It often co-exists with the wild type HCMV virus, 
which is not surprising as multiple HCMV strains are known to exist in the same individual 
(Chou, 1989). 
There are several studies that could not find the HCMV genome in tumour tissue using PCR 
assays (Baumgarten et al., 2014; Holdhoff et al., 2016) or NGS (Tang et al., 2015). One 
possible explanation is that there could be more deletions or mutated segments in this 
CMVIE△int2 variant genome. As expected, we also observed that the nested PCR is more 
sensitive than standard PCR or Taqman PCR for the detection of the CMVIE△int2 variant. Our 
results suggest that very few copies of the CMVIE△int2 variant DNA are present in cancer 
tissue samples, and thus, it would be difficult, or even impossible, to detect using the non-target 
specific next-generation sequencing (NGS) methods, as this method is not sensitive enough for 
detection of the rare copies of the DNA or RNA among all cellular DNA copies (Depledge et 
al., 2011). We propose that a high sensitive / target specific NGS of cancer samples is required 
(ongoing work using the Sure Select strategy) to identify the entire genome of this variant virus. 
To further verify that the CMVIE△int2 variant is not a contaminant of our lab, we examined a 
cohort of GBM tissues in Prof Bartek's laboratory in Copenhagen. The variant was found in 6 
of 70 (7%) examined glioblastoma tissue samples using new reagents and primers. 
Surprisingly, these results were much lower than that of observed in our laboratory. We are in 
the process of the finding out why the prevalence varies among the two labs, the collection and 
handling of the samples is a very critical step to be considered and furthermore, the prevalence 
could be different in a different population and variations of the CMV variant may also exist 
in different populations; these investigations are currently ongoing. 
The localisation of the HCMV DNA in these cells has been studied using FISH. A perinuclear 
localisation of the HCMV nucleic acids was observed in primary glioblastoma cells, in contrast 
to the nucleus of in vitro HCMV infected normal cells, cancer cell lines or blood cells from 
healthy individuals. 
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CMVIE△int2 variant is associated with detection of small IE reactive proteins 
We were interested to investigate further which MIE proteins could be detected in these tumour 
tissues and cells infected with the CMVIE△int2 variant. HCMV MIE proteins were detected 
in 79/80 (99%) and 30/33 (91%) of tumour samples by immunohistochemistry and flow 
cytometry, respectively. Furthermore, flow cytometry revealed that 27 of 30 (90%) 
glioblastoma tissue samples and 6 of 7 (86%) primary glioblastoma cell cultures expressed 
HCMV MIE proteins. These results were consistent with previously published observations 
(Cobbs et al., 2002b; Harkins et al., 2002; Harkins et al., 2010; Samanta et al., 2003b). 
Furthermore, we performed Western blot analysis of 59 tumour samples (15 primary 
glioblastomas, 10 primary glioblastoma cell cultures, 18 neuroblastomas, 12 breast cancers and 
3 colon cancers). Although in few cases the expected predominant IE proteins were detected 
(55, 72, and 86 kDa), smaller IE-reactive proteins (40, 36, 32, 26, 19, 12 kDa) at various levels 
were the most frequently observed (55/59 samples, 93%) in tumour specimens. 
During HCMV infection in vitro, multiple MIE mRNA species are made by differential 
splicing and polyadenylation (Awasthi et al., 2004) from five exons in the MIE genes UL122 
and UL123 (Castillo & Kowalik, 2002a; Stenberg et al., 1989; Stenberg, 1996). The IE1-p72 
protein is encoded by exons 2, 3, and 4 and the IE2-p86 by exons 2, 3, and 5 (Castillo & 
Kowalik, 2002a). The two major gene products, IE1-p72 protein and IE2-p86, regulate the 
expression of the majority of the HCMV genes and act as trans-activators for early and late 
gene expression. Although IE-86 protein is essential for replication of the virus, IE-72 is not 
(Marchini et al., 2001). Five additional transcripts are initiated from exon 2 (IE2-p55, IE28, 
IE19, IE17.5 and IE9), and two splice variants of IE86 (IE40 and IE60) have been described 
(White et al., 2007). These transcripts are expected to produce proteins of 60, 55, 40, 38, 31, 
19, and 9 kDa, however, their functions are unknown (importantly, how they affect the 
replication of the virus is also unknown), and they have not been studied in vivo. We propose 
that the IE reactive proteins we detected in tumour specimens represent HCMV IE splice 
variant proteins. However, this has so far not been possible to confirm with 
immunoprecipitation and Mass spectrometry analyses. Additional studies are therefore highly 
warranted to investigate the identity of these proteins further and to explore the functional role 
of these proteins in tumorigenesis. Importantly, deletion of intron-2 might be affecting the 
splicing process of the IE pre-mRNA and might lead to the expression of the different IE 
proteins observed. 
Isolation of the CMVIE△int2 variant strain 
To isolate the intron-2 deleted HCMV strain, we investigated 110 clinical isolates, three of 
these were positive for both CMVIE△int2 variant and wildtype virus. From one of these 
isolates, C26, CMVIE△int2 was successfully recovered in fibroblasts (MRC-5) and endothelial 
(HUVEC) cells. Both viruses initially replicated in this two cell types as confirmed by the 
expression of HCMV MIE, pp65 and gB proteins. Some IE proteins seemed to be localized in 
the cytoplasm of infected cells instead of the typical nuclear localisation, and western blot 
analyses detected IE proteins smaller as well as heavier than 70 kDa. We successfully purified 
the HCMV variant in HUVEC but not in fibroblasts. HUVEC cells infected with the HCMV 
variant showed aberrant looking plaques and small round cell structures, or cell nests, which 
were very typical for this virus. In the HCMV variant positive HUVEC cells, only dense bodies 
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were observed by electron microscopy but not the typical HCMV virus particles. In MRC-5 
cells infected with the C26 isolate (containing both the variant and the wild-type virus), all 
types of HCMV particles were visible: virus particles, non-infectious virus particles and dense 
bodies. These results indicate that the HCMV variant that was plaque purified was replication 
defective, expressed IE splice variant proteins, it was cell associated and did not cause a lytic 
infection. It was hypothesised that cells expressing IE proteins in the absence of lytic virus 
replication might undergo transformation since expression of IE-72 and IE-86 is mutagenic and 
resulted in tumour transformation in the presence of the adenovirus E1A protein (Shen et al., 
1997a). 
In primary cell cultures from glioblastoma patients, we found the variant in three well-
characterized cell cultures; GBM30, GBM42 and GBM48. HCMV MIE proteins were detected 
both in the cytoplasm and the nucleus in GBM30 and GBM42 cells, while GBM48 cells 
exhibited nuclear localisation of IE proteins, as is expected in wild-type HCMV infection. 
Nested PCR analysis confirmed that GBM30 and GBM42 are positive for the HCMV variant 
and GBM48 is positive for wild-type HCMV and the variant. By western blot analysis, approx. 
a 70 kDa HCMV IE protein, as well as several IE reactive proteins of smaller sizes, were 
detected; similar in all three cell lines. Immunohistochemistry, as well as immunofluorescence 
showed the characteristic cytoplasmic IE protein staining pattern observed previously in 
HCMV variant positive cells. By Electron microscopy analysis, dense bodies were visible and 
virus-like structures in some cells, none, however, resembling typical HCMV particles.  
The high prevalence of HCMV in different types of cancer and the detection of a HCMV 
variant is clinically relevant and may introduce anti-viral drugs as a new approach for treatment 
of cancer patients. Our group was the first to treat glioblastoma patients with anti-HCMV 
therapy as an adjuvant to their standard therapy. Follow-up assessments showed a significantly 
longer survival among patients who received valganciclovir treatment ((Söderberg-Nauclér  et 
al., 2013) and unpublished results). The fact that most of these patients may be positive for the 
HCMV variant, which appears to be replication defective, raised the question of how anti-viral 
drugs affect this virus. To assess whether anti-viral treatment could affect tumour growth in the 
presence of the HCMV variant, primary glioblastoma cell lines previously described (GBM30, 
GBM42 and GBM48) were treated with 1 µM or 2 µM Ganciclovir or left untreated. We 
observed that treatment with the anti-HCMV drug ganciclovir inhibited proliferation of 
GBM30 and GBM 42 cells by about 60% at 7 days and reduced IE protein expression. 
 
In summary, we report for the first time the existence of the CMVIE△int2 variant, which is highly 
associated with tumours. This discovery may provide new insights into the potential role of 
HCMV in cancer and may explain the conflicting data that has been obtained by different research 
groups. Thus, our methods described herein offer diagnostic tools to identify individuals who are 
carriers of the CMVIE△int2 variant and allows for studies to evaluate whether this virus can be 
transferred through blood, breast milk and organ transplants. The clinical relevance of this new 
variant virus and its biological impact in different types of cancer warrants further investigation.  
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4.2 STUDY-II 
Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid 
arthritis, diabetes mellitus and healthy controls  
Background 
Inflammation plays a very critical role in reactivation of latent HCMV infection (Soderberg-
Naucler et al., 2001; Söderberg-Nauclér et al., 1997). Thus, it is not surprising that HCMV 
infection is associated with several inflammation associated diseases such as, cardiovascular 
diseases (CVD), Rheumatoid Arthritis (RA), Glioblastoma multiforme (GBM) and Diabetes 
Mellitus (DM) (Cobbs et al., 2002a; Lucas et al., 2011; Mitchell et al., 2008; Rahbar et al., 
2012b; Tamm et al., 1993). The miR-UL-112 is a HCMV encoded miRNA that targets host 
and viral RNA transcripts and is linked to latency, and circulating miR-UL112 is associated 
with hypertension. In this study, serum/ plasma of patients with DM, GBM and RA, and 
Healthy Controls (HC) were analysed by ELISA for quantification of HCMV IgG and IgM 
levels and standard miRNA Taqman assay for the quantification of miR-UL112 levels. 
Results and discussion 
Samples from patients diagnosed with GBM, DM or RA and HC (87 plasma/serum) were 
collected and examined for the prevalence of HCMV IgG, IgM and miR-UL112-3p. The 
prevalence of the HCMV IgG is 85% (23/27) in DM; and not significant when compared with 
HC. In contrast to our results, Roberts et al. found a higher prevalence and significantly 
different levels of HCMV IgG compared with HC in San Antonio population (Roberts & Cech, 
2005). Another study found that HCMV IgG is associated with various indicators of glucose 
regulation and found high prevalence of HCMV IgG to be a risk factor for the development 
diabetes in the elderly (Chen et al., 2012). In this study, the HCMV-IgG prevalence was 65% 
(13/20) in GBM patients, and not significantly different as compared with the HC. In contrast 
to our results, a higher prevalence and significance results were obtained in Iraqi populations 
(Shamran et al., 2015). The prevalence of HCMV IgG is not associated with risk of developing 
GBM (Susan Amirian et al., 2013). However, our recent study demonstrated that the IgG 
negative patients with T-cell reactivity against HCMV peptides were positive for HCMV in 
their tumours and blood cells. Suggesting HCMV IgG may not be a good indicator of the 
HCMV activity in GBM patients (Rahbar et al., 2015). We found HCMV-IgG in (14/20) 70% 
RNA patients, and significantly higher IgG OD values were observed in RA patients compared 
with HC (p=0.009), Similar results were obtained in another study (65.3%), and was shown to 
be associated severe joint disease (Pierer et al., 2012). 
Furthermore, the prevalence of HCMV IgM was found only in one of 20 (5%) GBM patients, 
all other patients and HC were negative. However, HCMV IgM OD values (background signal) 
were significantly higher in DM patients as compared with HC (p=0.03).  
We found that 52% (14/27) of DM patients, 25% (5/20) of GBM patients, 5% (1/20) of RA 
patients and 10% of HC were positive for miR-Ul112-3p with 8, 4, 1 and 1 mean copies/10 ng 
of RNA, respectively. Overall DM patients had significantly higher levels of miR-UL112-3p 
than HCs. Moreover, no significant correlation was found between miR-UL112-3p levels and 
HCMV IgG or IgM OD values. To our knowledge this is the first study to examine the HCMV 
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miRNA miR-UL112 in these diseases and linked to DM patients. Elucidation of miR-UL112-
3ps functions in DM pathogenies needs further investigations.  
The miR-UL112-3p is expressed during active (Shen et al., 2014), latent infection and natural 
infection (Meshesha et al., 2016). The miR-UL112-3p  acts as a translational repressor of 
HCMV IE-72 and prevents the production of early and late proteins and is proposed to favour 
latent infection by suppressing the viral replication (Grey et al., 2007; Murphy et al., 2008). 
Furthermore, several studies have found that miR-UL112-3p mediates immune evasion 
strategies so that the virus can be maintained in its host and avoid elimination by the host 
immune response. For example, miR-UL112-3p downregulates IL-32 and MICB, which 
prevents NK cell recognition and facilitates the establishment and maintenance of latency 
(Huang et al., 2013b; Stern-Ginossar et al., 2007).  
Accumulating evidence suggests that the miRNAs are packed into microvesicles that are 
released from infected cells (Lasser et al., 2011; Valadi et al., 2007). Thus, we speculate that 
miR-UL112-3p released into the blood circulation from several cell types such as macrophages, 
monocytes, endothelial cells or even tumour cells. So far, however, there are no studies that 
have characterised the miRNA content of the microvesicles derived from HCMV infected cells. 
Importantly, based on the described functions of miR-UL112-3p, the presence of this viral 
miRNA in the screened patients might have an impact on disease progression.  
Li et al. showed that miR-UL-112 was highly expressed in the Chinese hypertension patients. 
Using luciferase assays, the miR-UL112 can target IRF-1, and proposed that this could 
upregulate angiotensin II type 2 receptor expression, which exerts antiproliferative and 
proapoptotic actions and regulates blood pressure. Another recent study found that miR-
UL112-3p is highly expressed in IE-86 positive GBM tissues (Liang et al., 2017). Patients with 
higher expression of miR-UL112-3p had lower tumour free survival and overall survival rates. 
Furthermore, overexpression of miR-UL112-3p in GBM cell lines promoted tumour clone 
formation, cell proliferation, migration and invasion. miR-UL112-3p was shown to target the 
tumour suppressor candidate 3 (TUSC3) protein. Thus, this study suggests that  miR-UL1122-
3p might promote tumour progression by downregulation of the Tumour suppressor candidate-
3 gene (TUSC3) (Liang et al., 2017). 
In summary, increased levels of miR-UL112-3p and higher prevalence and elevated levels of 
HCMV IgG were observed in DM patients as compared with HC. Higher prevalence of miR-
UL112-3p was found in DM and GBM patients as compared with RA patients and HC. 
Whether miR-UL112-3p levels in the blood can serve a mediator of biological effects or 
representing a biomarker of the disease and/or HCMV latency warrants further investigations. 
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4.3 STUDY-III 
Human Cytomegalovirus MicroRNAs are carried by Virions and Dense Bodies and are 
delivered to Target Cells. 
 
Background 
A lytic HCMV infection results in the production of mature virions, dense bodies (DBs) and 
Non-infectious enveloped particles (NIEPS) (Craighead et al., 1972; Stinski, 1976; Talbot & 
Almeida, 1977a). All these particles consists of host and viral encoded proteins (Baldick & 
Shenk, 1996; Stinski, 1976; Varnum et al., 2004) and long RNA molecules (Greijer et al., 
2000; Huang & Johnson, 2000; Lin et al., 2012; Sarcinella et al., 2004; Terhune et al., 2004). 
In this study, we investigated whether these particles also contain miRNAs, and further 
examined if these miRNAs are functional when delivered to the host cells. 
Characterization of virions and DBs 
We isolated the virions and DBs from supernatants obtained from the HCMV infected MRC5 
cells using ultracentrifugation with potassium-tartrate glycerol gradients. The isolated virions 
and DBs were visualized with electron microscopy-negative staining, the presence of HCMV 
genome, and pp65 proteins, and absence of host genome was determined by different assays. 
Surprisingly, we found almost similar amounts of DNA content in both virions and DBs. DBs, 
however, have less viral genome copies and less infectivity rate than virions (68.4 % in virions 
vs 3.8% in DBs). Furthermore, the infectivity observed with DBs could be caused by the 
contamination of few virions in the DBs preparations, as previously described by several 
reports (Pepperl et al., 2000; Sarcinella et al., 2004; Talbot & Almeida, 1977a), and thus would 
be expected to be infectious (Sarcinella et al., 2004). Consistent with our study, the pp65 
protein was found in DB preparations, but these studies did not search for viral DNA (Baldick 
& Shenk, 1996; Varnum et al., 2004). Interestingly, one early study contradicts these results. 
However, Irmiere et al, did not find HCMV DNA or the amino acids in the DB sample, thus 
indicating that there was no DBs present in the examined sample preparation (Irmiere & 
Gibson, 1983).  
miRNA, mRNA and lncRNAs are incorporated into virions and DBs 
Before the isolation of the virions and DBs, the pellets (virus stock) were treated with RNase-
ONE and, later, with the micrococcal nuclease to remove all nucleic acids. We found RNA 
molecules in both virions, and DBs samples, which we initially determined with NanoDrop 
then characterised with Agilent bioanalyzer analysis and further investigated with TaqMan 
PCR assays. Bioanalyzer analysis of RNA obtained from virions and DBs using two different 
kits found various RNA species in size ranges from 6 - 4000 nucleotides, which will include 
miRNAs, small RNAs and long RNA molecules. There was very little amount or no 18S and 
28S rRNAs detected in virions and DBs. In contrast, cellular RNA samples had the highest 
content of these rRNAs. As the 18S and 28S are long RNAs and associated with ribosomes, 
they might not be incorporated into the particles. To our knowledge, our study is the first to 
perform the bioanalyzer analysis of the RNA molecules prepared from virions and DBs.  
The viral transcripts IE and lncRNA2.7, and cellular transcript B2M were detected in both 
virions and DBs at different levels by TaqMan PCR assays. The presence of these viral 
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transcripts has been previously examined only in virions (Greijer et al., 2000; Terhune et al., 
2004) (Bresnahan & Shenk, 2000). The purpose of their presence in the viral particles, 
however, has not been fully elucidated. The incorporation of the RNA molecules into the 
particle was suggested to be random, and concentration dependent (Terhune et al., 2004), but 
another study reported that only a subpopulation of RNA molecules get incorporated into the 
virions (Bresnahan & Shenk, 2000) indicating there may be some selection involved. In this 
study, we found that IE and lncRNA2.7 levels in cells and particles had similar patterns, 
suggesting a concentration depence in incorporation. The translation of the delivered RNA has 
been determined but functional studies have not been performed (Bresnahan & Shenk, 2000). 
There are RNA transcripts which are found to hybridise with the viral DNA and proposed to 
mediate the replication of this virus by acting as an RNA primer (Prichard et al., 1998b).  
Among herpesvirus family members such as herpes B virus (Amen & Griffiths, 2011a), KSHV 
(Lin et al., 2012) and EBV (Jochum et al., 2012), it has been demonstrated that miRNAs are 
present in virions. Furthermore, delivery and function of the miRNAs from KSHV particles 
was studied using a luciferase reporter assays and were shown to be functional  (Lin et al., 
2012). One previous study reported that HCMV small RNAs are abundantly expressed in the 
infected cells (Stern-Ginossar et al., 2012). However, this is the first report determining the 
presence of HCMV miRNAs in different particles, virions and DBs. Here, we show the 
presence of 14 HCMV miRNAs (UL22A-5p, US25-1-5p, UL22A-3p, US5-2-3p, UL112-3p, 
US25-2-3p, US25-2-5p, US33-3p, US5-1, UL36-5p, US4-5p, UL36-3p, UL70-5p, and US25-
1-3p)  and 2 host miRNAs (hsa-miR-218-5p and hsa-miR-21-5p) in virions and DBs at 
different levels. Interestingly, the two miRNAs (UL70-5p and US25-1-3p) expressed in lowest 
abundance were found in both virions and DBs, but not in infected MRC-5 cells. We speculate 
that virions and DBs protected these two miRNAs from the cellular nuclease activity, whereas 
in cells these miRNAs were degraded. The overall pattern of these 14 viral miRNAs levels in 
these particles, are similar to that of infected MRC-5 cells, suggesting that it may be a 
concentration dependent incorporation. However, we do not know which other miRNAs are 
present in the particles and their functions, a next generation sequencing study may be required 
to fully elucidate whether all the miRNAs (HCMV and host encoded) are present in virions 
and DBs.   
Virions and DBs can transfer viral miRNA to the host cell and be functional 
To investigate if these miRNAs from virions and DBs are delivered to host cells and can be 
functional, both particles were subjected to UV-irradiation to inactivate the virus ability to 
replicate, and thereafter incubated with MRC-5 cells. The efficiency of inactivation of the virus 
with UV-treatment was determined using immunostaining against IE proteins 3 hours later. A 
cytoplasmic staining of IE proteins was observed, but this staining pattern disappeared 1 day 
later, indicating that IE proteins / RNA molecules are indeed delivered to the target cells. We 
did not find the IE or lncRNA2.7 transcripts in cells at 1d post treatment with UV-treated 
particles.  Furthermore, we also examined three miRNAs and found two miRNAs; miR-US25-
1-5p and miR-UL112-3p in cells incubated with UV-treated virions or DBs.  
Among the detected 14 miRNAs, miR-US25-1-5p was the most abundantly expressed. To 
investigate if the delivered miR-US25-1 was functional, we used a luciferase reporter plasmid 
containing the 5’UTR of the CCNE2 gene (CCNE2) and a plasmid containing a mutation at 
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the miRNA binding site (MUT-CCNE2) previously described (Grey et al., 2010a). We found 
that both UV-inactivated virions and DBs significantly decreased the luciferase levels in cells 
transfected with CCNE2 luciferase plasmid (12% with virions p=0.02 and 8% with DBs 
p=0.03), but only a 5% decrease in the MUT-CCNE2 luciferase levels. However, the 
observation that virions and DB still have an effect on luciferase levels when the miRNA-
binding site is mutated suggest an off-target effect of delivered miRNAs or that signalling event 
may interfere with the luciferase levels. To address this questions further and strengthen the 
conclusions from this assay, we used virions and DBs isolated from a miR-US25-1 knockout 
virus and wild-type HCMV virus and increased the number of particles used for the experiment. 
Consistent with earlier experiments, luciferase levels in cells transfected with the CCNE2 
plasmid and infected with WT-virions were significantly lower than in cells infected with miR-
US25KO-virions (21% vs. 4% reduction). Similar results were obtained using the HCMV WT-
DBs and miR-US25KO-DBs. There was no significant effect on luciferase levels in MUT-
CCNE2 transfected cells when incubated with particles from WT or KO samples.   
HCMV encoded miRNAs have been found to be key regulators of immune functions by 
targeting receptors to avoid recognition by immune cells or by inhibiting production of pro-
inflammatory cytokines and molecular mechanisms of latency and reactivation (see chapter-
III). More specifically, in in vitro studies using wild type HCMV and knock out virus infection 
or miRNA overexpression, it has been demonstrated that the miRNA-US25-1 targets the 
5´UTRs of multiple cell-cycle-regulating genes such as CCNE2, H3F3B, and TRIM 28 (Grey 
et al., 2010a) and several cellular genes (YWHAE, UBB, NPM1, and HSP90AA1), which can 
affect viral replication (Jiang et al., 2015). Thus, our results suggest that when HCMV virions 
or DBs deliver miRNAs to the host cells, it affects various pathways by regulating several 
proteins. 
In conclusion, this study shows that HCMV-encoded miRNAs are present in virions and DBs 
and can be delivered to cells. We provide proof of principle data that viral miRNAs can be 
delivered from virions and DBs to host cells and be functional, altering the expression of viral 
and cellular proteins and, thus, perhaps playing important roles in HCMV biology.  
  
 58 
4.4 STUDY-IV 
High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast 
cancer and metastatic sentinel lymph nodes 
Background (for study-IV and -V) 
Worldwide Breast cancer is the most common cancer and a leading cause of death in women 
(reviewed in (Key et al., 2001)).  Breast cancer comprises 22% of all cancers in women 
(Dumitrescu & Cotarla, 2005). Several risk factors such as age, family history, diet, alcohol, 
etc have been associated with the breast cancer. The causes of breast cancer initiation are not 
known (Dumitrescu & Cotarla, 2005). In-depth studies have been performed to identify 
additional risk factors which may contribute to the disease. Apart from the environmental and 
epidemiological factors, some recent studies have focused on viral infections. It has been 
proposed that viral infections are responsible for about 20% of all malignancies worldwide 
(Kuper et al., 2000). 
Several studies have found the presence of the oncogenic viruses EBV and HPV in breast 
cancer (Heng et al., 2009; Labrecque et al., 1995). However, other studies could not confirm 
the presence of these viruses in breast cancer (Herrmann & Niedobitek, 2003; Silva & da 
Silva, 2011). This has created an increased interest to find other viral agents in breast cancers, 
but this also created enhanced controversial discussions in this field (Lawson et al., 2006). As 
discussed elsewhere in this thesis, HCMV proteins confer pro-oncogenic properties. This virus 
has been extensively searched for in several types of cancer, and experimental studies are 
performed to elucidate whether this infection plays a major role in cancer development or 
progression. 
To our knowledge, an association between HCMV and breast cancer was first found by 
Richardson et al. in 1997. They found that HCMV IgG antibody titers were higher in breast 
cancer patients than in healthy controls, and these data are consistent with data from more 
recent studies (El-Shinawi et al., 2013; Richardson, 1997; Richardson et al., 2004). 
Furthermore, several studies found the presence of the HCMV infection in the patients with 
breast cancer (El-Shinawi et al., 2013; Harkins et al., 2010; Tsai et al., 2005), and others have 
reported a lack of evidence of HCMV nucleic acids in breast cancer specimens (Utrera-Barillas 
et al., 2013). Several studies have reported a high prevalence of HCMV protein expression in 
the normal glandular epithelium (Harkins et al., 2010; Tsai et al., 2005), in contrast, El-Shinawi 
found less prevalence of the HCMV in normal glandular breast tissue specimens (El-Shinawi 
et al., 2013). 
Whether HCMV is present in breast cancer or not is under debate today. Accumulating 
evidence suggest a high prevalence of HCMV infection in various types of malignancies. 
However, it was not clear whether HCMV is also present in the metastatic tumours. In this 
study, we investigated the prevalence of HCMV infection in breast cancer primary tissues and 
its paired sentinel lymph node specimens (SLN). We used a TaqMan assay for viral DNA 
detection and IHC for the detection of viral proteins. To assess the association between HCMV 
infection and known clinical parameters, a statistical analysis was performed. 
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Results and discussion 
High prevalence of HCMV infection in breast cancer and paired sentinel lymph node 
specimens 
We collected breast cancer and paired sentinel lymph node (SLN) tissue specimens fixed in 
formalin-fixed-paraffin-embedded from breast cancer patients with (n=35) and without SLN 
metastasis (n=38). To detect the viral proteins, we used a high sensitive immunohistochemistry 
(IHC) method adapted from Cobbs et al and optimised (Cobbs et al., 2002c; Taher et al., 2013) 
and developed a TaqMan PCR assay for detection of HCMV nucleic acids. 
We identified HCMV IE and LA proteins using IHC in all breast cancer specimens (n=73). 
Our findings were consistent with the results reported by Harkins et al (Harkins et al., 2010), 
suggesting a high prevalence of HCMV proteins in breast cancer tissues. Both HCMV IE and 
LA proteins were detected in 94% of SLN positive samples and 60% of the SLN-negative 
group. HCMV proteins were present in the majority of metastatic tumours in SLN samples. 
Few HCMV-positive inflammatory cells were also found in 79% of SLN samples with 
metastasis, and very few HCMV-positive inflammatory cells were also detected in 60% of 
metastasis-free SLNs. The higher prevalence of HCMV in SLN samples might be due to the 
HCMV activity, infection of neuroblastoma cells increase the tumor cell adhesion and disrupts 
the endothelial cell monolayer integrity and favours the transendothelial migration, suggesting 
that HCMV infection increase the invasiveness (Scholz et al., 1999; Streblow et al., 1999). 
Furthermore, HCMV infection induces production of TGF-beta1 via inducing MMP-2 
(Shimamura et al., 2010). In theory, MMP-2 can mediate the degradation of extracellular 
matrix (Reinhardt et al., 2006). HCMV induced TGF-beta production and facilitated an EMT 
process (Michelson et al., 1994). Furthermore, infected epithelial cells treated with TGFB in 
vitro study shows a similar EMT process (Shimamura et al., 2010). 
We graded the tumour tissues based on the percentage of HCMV IE and LA positive cells. 
Sections were graded as negative (0), grade I (< 25% positive cells), grade II (25-49%), grade 
III (50-75%) or grade IV (> 75%). In both in the SLN-positive and -negative groups, we found 
that the majority of breast samples were of high HCMV grade (grade III and IV). These results 
were consistent with our previous findings of a high prevalence of HCMV protein detection in 
other tumours as well (study-I; (Rahbar et al., 2012a; Taher et al., 2013; Wolmer-Solberg et 
al., 2013)). Most common grades for HCMV LA proteins were grade II and III, HCMV LA 
protein expression was less abundant than IE. These results indicate that there was a non-
productive viral infection in these tissues. HCMV IE grade III and IV accounted for 76 % of 
the SLN positive samples, suggesting that most metastatic cells were IE positive. We also noted 
that IE protein expression was higher in the primary tumours than in SLN tissues. The HCMV 
IE protein expression grade was also higher in primary breast cancer specimens as compared 
with the SLN tissue specimens. Importantly, we noted that HCMV protein expression was 
mostly restricted to tumour cells, although some inflammatory cells were also stained positive 
for IE proteins.  
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High HCMV infection grade in breast cancer tissue specimens was observed in patients who 
died of breast cancer 
In glioblastoma patients, we found a strong association between low-grade HCMV infection in 
the glioblastoma tumour at the time of diagnosis and prolonged survival, which implied that 
HCMV might be involved in tumour progression (Michaelis et al., 2009; Rahbar et al., 2012a). 
Furthermore, HCMV infection grade was associated with shorter time to tumour metastasis 
and shorter survival after diagnosis of distal metastasis in colon and breasts cancer patients 
(Taher et al., 2014). In this study cohort, only seven patients died of breast cancer; this did not 
allow for further statistical analyses of a viral impact on survival. However, we noted that six 
of seven patients who died of breast cancer had high-grade HCMV infection (grade IV), while 
patients with low IE expression were all among the survivors. These observations imply that 
HCMV may influence survival and tumour progression, and HCMV targeted therapies may 
improve the outcome of patients. 
 
HCMV infection level did not correlate with clinical prognostic factors 
Estrogen receptor alpha (ER-α) and progesterone receptor (PR) expression status and Elston 
grade are well established prognostic markers for breast cancer patients, which also influence 
selection of patient treatment. Loss of ER-α and PR expression are predictors of poor survival 
(Slobedman & Mocarski, 2012). The Elston-Ellis histopathological grading provides 
significant prognostic information for breast cancer patients by assessing tubular formation, 
mitotic activity and nuclear pleomorphism. Furthermore, Elston grade I tumours have a 
significantly better survival than those with grade II and III tumours (Dalton et al., 1994). 
In breast cancer patients, we recently found an inverse correlation of high-grade HCMV 
positivity with the loss of expression of ER-α and PR, and a trend for reduced HER-2 
expression (under review). Furthermore, in our study-V, in vitro experiments showed that ER-
α and PR are downregulated by the HCMV encoded miRNAs. In this study, we did not find 
any significant association between HCMV infection grades and these prognostic indicators. 
This could be due to a selection of earlier cases of breast cancer, or to a low power of the study. 
Although the presence of an infectious agent in tumour tissues does not provide evidence for 
its cause of carcinogenesis, the presence of HCMV in both primary tumour and in most SLN 
metastases tissues, supports the hypothesis that HCMV plays an active role in tumorigenesis 
and metastasis development in breast cancer patients. Therefore, further studies are highly 
warranted to evaluate the possible mechanisms contributed to breast cancer tumorigenesis and 
metastatic diseases. 
In an in vitro study, HCMV infection of neuroblastoma cells increased the tumor cell adhesion 
and disrupted the endothelial cell monolayer integrity and favoured trans endothelial migration, 
suggesting that HCMV infection increase the invasiveness and also trans-endothelial migration 
(Scholz et al., 1999). This might be mediated by HCMV chemokine receptor US28 (Streblow 
et al., 1999). 
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4.5 STUDY-V 
A potential role for human cytomegalovirus in triple negative breast cancer through 
its specific mechanisms to downregulate ER-α, PR and HER-2 
Background  
Breast cancer incidence is still increasing, although the mortality is decreasing (Ferlay et al., 
2015). As described earlier, the expression of estrogen receptor alpha (ER-α), progesterone 
receptor (PR) and human epidermal growth factor receptor-2 (HER-2) are three very 
important prognostic markers to guide therapy (Hayes, 2005; Hortobagyi et al., 1983).  Breast 
cancer subtypes that lacks the expression of ER-α, PR, and HER-2 are known as a triple-
negative breast cancer (TNBC), and these patients have a significantly worse outcome (P 
Kourea et al., 2014; Perou et al., 2000; Sørlie et al., 2001). Breast cancer patients who have 
been treated with ER- modulators such as Tamoxifen and the ER-α antagonist fulvestrant, 
have reduced mortality and recurrences (Dalmau et al., 2014). Similarly, HER-2 
overexpressing breast cancer patients were treated with Trastuzumab (Herceptin) (Ahmed et 
al., 2015), which increased overall survival (Slamon et al., 2001). However, none of these 
treatments can be offered to TNBC patients, and a significant number of patients do not 
respond these therapies (Ahmed et al., 2015; Fan et al., 2015). Although, breast cancer 
treatment has been advanced and improved the survival during the last few decades, still for 
the TNBC patients are in need new therapy strategies. Several factors are linked to malignant 
transformation and tumour progression of the breast cancers, including many viruses. A 
general background of breast cancer and associations with HCMV has been described in the 
beginning of study-IV. 
In breast cancer patients, we recently found an inverse correlation of high-grade HCMV 
positivity with the loss of expression of ER-α and PR, and a trend for reduced HER-2 
expression (under review). These findings suggest that regulating the activity of HCMV in 
tumours could represent a new therapeutic option for HCMV positive cancer patients. We 
hypothesised that this virus might affect the expression of these receptors in breast cancer. In 
this study, we found that three HCMV encoded miRNA (hcmv-miR-US25-2-3p, hcmv-miR-
UL36-3p and hcmv-miR-UL22A-3p) can downregulate ER-α and PR receptors. To date, 26 
HCMV miRNAs have been identified in HCMVs genome (www.mirbase.org), and these 
miRNAs regulate several biological processes (described in chapter-III of this thesis). 
 
Results and discussion  
HCMV infection downregulates ER-α, PR and HER-2 in breast cancer cell lines 
In this study, we demonstrate that HCMV in vitro infection downregulates the expression of 
ER-α, PR and HER-2 in breast cancer cell lines MCF-7 (ER+/PR+) and SKBR3 (HER-2+). 
The effect of HCMV was observed at mRNA and protein levels as shown by qPCR and western 
blot/immunofluorescence, respectively. Furthermore, downregulation of these three receptors 
was not affected by UV-irradiated HCMV, which suggest that viral gene expression is required 
to regulate the expression of these receptors. Similar results were obtained in an ovarian cancer 
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cells, SKOV-3. HCMV infection of the triple negative breast cancer cell line, MDA-MB-231 
had no effect on the undetectable or low expression levels of ER-α, PR and HER-2.  
HCMV IE and Late proteins does not affect ER-α or HER-2 levels in breast cancer cell lines 
In our in vitro infection experiments, UV treated virus did not affect the expression of ER-, 
PR and HER-2 levels suggesting that translation of viral gene products is essential, and 
signalling events caused by the virus entry is not involved in downregulation of these receptors. 
As discussed earlier in chapter-II elsewhere in this thesis, HCMV gene products have been 
shown to be involved in almost all biological processes such as cell cycle dysfunction, 
immortalization, genomic instability, etc. We hypothesised that the downregulation of ER-α, 
PR and HER-2 is also mediated by the viral proteins. To block the viral replication and late 
proteins production, we treated the breast cancer cells with ganciclovir (GCV) during infection 
with HCMV. Treatment of HCMV infected MCF-7 or SKBR3 cells with GCV, did not revert 
the downregulation of ER-α, PR or HER-2 expression, respectively, which indicate that late 
viral gene products are likely not involved in the regulation of ER-α, PR or HER-2 expression, 
but could be mediated by the IE and E proteins. 
We next assessed if the IE-72 proteins (acts as trans-activator protein for the expression cascade 
of HCMV genes) could regulate these three receptors, and found that knock-down of IE-72 
with siRNA had no effect on any of these three receptors. These results suggest that IE-72 has 
no role in downregulation of ER-α, PR and HER-2. However, it could be mediated by the other 
IE proteins. 
HCMV miRNAs target ER-α and PR expression in breast cancer cell lines 
Cellular and viral miRNAs are well known regulatory molecules to downregulate gene 
expression. We identified three HCMV encoded miRNAs (hcmv-miR-US25-2-3p, hcmv-miR-
UL36-3p and hcmv-miR-UL22A-3p), which are predicted to target the ER-α; moreover, the 
hcmv-miR-UL22A-3p was also predicted to target PR. However, none of the HCMV encoded 
miRNAs are predicted to target HER-2 directly. It is possible, however, that HCMV regulates 
HER-2 indirectly through a cellular miRNA (ongoing work). We found that  all these putatively 
predicted HCMV miRNAs are expressed at different levels in MCF-7 as well in MRC-5 
infected cells. The levels of all the three miRNAs were higher in MRC-5 cells than in MCF-7 
cells, this could be due to higher permissiveness in MRC-5 cells. The accumulation of the 
expressed miRNAs in MCF-7 cells with time was inversely associated with the downregulation 
of ER- and PR. Similar to our results, these miRNAs were also found in infected Human 
Lung Fibroblast and suggested to be expressed at either ‘immediate early or early’ times  (Shen 
et al., 2014). miR-UL22A-3p is the first miRNA among others (initially called miR-UL23) 
found in infected fibroblast, endothelial, epithelial and astrocyte cells  (Dunn et al., 2005). 
Furthermore, miR-US25-2-3p (Fu et al., 2014) and miR-US36-3p (Meshesha et al., 2016) are 
expressed in the in vitro latent infection models, and miR-UL36-3p is found in monocytes of 
healthy blood donors (Meshesha et al., 2016). 
  63 
The bioinformatics predictions were confirmed experimentally by overexpression of these 
three miRNAs in MCF-7 cells. All the miRNAs were able to downregulate ER-α and PR at 
transcript and protein level (only ER-α). Although hcmv-miR-US25-2-3p and hcmv-miR-
UL36-3p are not predicted miRNAs to target PR, still PR expression was decreased by these 
miRNAs, which might be expected since it has been described that ER-α regulates PR 
expression.  
TNBC tumours have a specific molecular signature which is mediated by several pathways 
(Ossovskaya et al., 2011). The mechanism of loss of ER-α, PR and HER2 in TNBC tumours 
is mostly unknown, germline mutation of BRCA1 gene is linked to the loss of these receptors 
(Chacon & Costanzo, 2010; Foulkes et al., 2003; Lakhani et al., 2005).  Our results suggest 
that HCMV infection may contribute to the development of a triple negative phenotype in 
breast cancer (TNBC), which is in part mediated by these viral miRNA. TNBC patients account 
for about 10-15% of the all breast cancers and have limited treatment options as they do not 
respond to endocrine therapy or HER-2-targeted treatment  (Gordon & Banerji, 2013). 
There a few in vitro studies that have investigated the role of these miRNAs; miR-US25-2-3p 
can target tissue inhibitors of metalloproteinase-3 (TIMP3), which leads to increased shedding 
of MICA proteins leads decrease recognition of infected cells by the NK cells (Esteso et al., 
2014). Over-expression of miR-US25-2-3p results in downregulation of Eukaryotic translation 
initiation factor 4A1 (eIF4A1), and this leads to inhibition of translation, inhibits the replication 
of the virus (Jiang et al., 2015; Qi et al., 2013). UL138 protein is known to be required the 
establishment and maintenance of latent HCMV infection (Goodrum et al., 2007a; Petrucelli 
et al., 2009), and overexpression of the miR-UL36 can downregulate UL138 during the first 
24h in the lytic cell models (Huang et al., 2013a). Although, these results needs to be validated 
in a latent infection model to show its significance on latency. In this thesis we have extensively 
discussed the HCMV miRNAs in chapter-III. 
Breast cancer tissues expresses HCMV miRNAs 
Our results indicate that HCMV regulates the expression of ER and PR in breast cancer through 
viral miRNAs. Thus, we investigated if these viral miRNAs can be detected in clinical samples 
and how it correlates with the subtype of breast cancer. So far, 10 HCMV DNA PCR positive 
breast cancer tissue samples were examined for the three HCMV miRNAs by qPCR. The 
hcmv-miR-UL22A-3p was detected in 8/10 samples, hcmv-miR-UL36-3p was detected in 7/10 
samples, while hcmv-miR-US25-2-3p was only detected in 3/10 samples. The expression of 
the each miRNA was highly variable among the examined miRNAs but there was only one 
sample negative for the three examined HCMV miRNAs. 
Our in vitro results suggested the downregulation of ER- and PR is mediated by the HCMV 
encoded miRNAs. Thus, HCMV targeted therapy may be a relevant alternative in breast cancer 
patients, although treatment with GCV did not restore the expression ER-, PR and HER-2. 
Therefore, we highlight the possibility that different antiviral drugs targeting HCMV should be 
tested. In glioblastoma patients, we earlier demonstrated that anti-viral therapy may improve 
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survival (Rahbar et al., 2012c). The presence of these miRNA in breast cancer tissues argues 
that they could lower the expression of ER-α and PR, and may thereby contribute to the 
development of TNBC. To be more specific, instead of anti-viral, treatment with anti-miRs or 
miRNA inhibitors against three viral miRNAs may restore the ER-, PR and HER-2, warrants 
further investigation. 
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5 CONCLUDING REMARKS 
 
We discovered a high prevalence of a novel genetic variant of HCMV in cancer specimens, 
which seems to represent a unique virus with pro-oncogenic capabilities. The altered behaviour 
of HCMV in tumours appears to be the explanations to controversies in the field, and that some 
investigators have failed to detect HCMV in cancer specimens. It is now critical to understand 
this variant virus role in more cancer types, and it is also essential to determine whether it 
spreads via blood products and organ transplants. At this moment, it is difficult to establish the 
association between cancer and this variant virus that exist in some healthy individuals, but in 
higher prevalence in cancer patients. 
 
HCMV serology was determined and the prevalence of the HCMV encoded miRNA, miR-
UL112 -3p was screened for in the blood of DM, RA, GBM patients and in HC’s. No 
association was found between serology and miRNA levels, but we observed that the miR-UL-
112 levels were significantly higher in DM patients than HC. On the basis of our results, others 
have found the oncomodulatory role of miR-UL112 in GBM.   
 
Novel virus-host interaction with miRNAs has been well established. We found that host and 
HCMV-encoded miRNAs in virions and DBs, demonstrated that these miRNAs can be can be 
delivered to the host cells, where they may alter cellular protein expression and may play 
biologically important roles especially during the early phase of the virus life cycle. 
 
HCMV´s role in breast cancer was elucidated. We detected HCMV proteins in significantly 
higher proportion in metastasis positive SLNs. Furthermore, we found that 99% of metastatic 
tumour tissues express HCMV proteins and nucleic acids. Despite improvements in the 
treatment of breast cancer, most deaths are due to metastasis. Therefore, a further understanding 
of the role of HCMV in the metastatic process of breast cancer is highly wanted. 
 
The ER-α, PR and HER-2 are the most important prognostic markers for breast cancer patients. 
We found that HCMV encoded miRNAs downregulate the expression of ER-α and PR, and 
HCMV infection downregulates the HER-2 in breast cancer cells, and this may contribute to 
triple negative breast cancer. These observations reveal that HCMV may play an important role 
in the pathogenesis of TNBC, and may give hope for a new therapy option to include anti-viral 
therapy in the treatment of these patients, who are in desperate need of new therapy options.  
 
In this thesis work, I together with my colleagues have worked on the several projects to 
understand the role of HCMV in its associated diseases in many different directions from 
finding a novel HCMV variant to its miRNAs and their potential links to several diseases. I 
believe that my thesis work covers the basic virology projects to advanced translation research 
projects, and by utilising a range of methods from basic methods to molecular biology methods. 
In several projects, we have used patient samples and liked their pathogenesis with HCMV 
infection, and I see a future in which the understanding of the relevance of this virus in different 
diseases is likely to increase, and in particular for cancer, such knowledge could lead to new 
treatment options for patients in a near future.   
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